Document:

<PAGE>

                                                                   Exhibit 10.27

          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.

                                SUPPLY AGREEMENT

This Supply Agreement (the "AGREEMENT") is entered into by and between:

NXSTAGE MEDICAL, INC., a company organized and existing under the laws of
Delaware, and having offices at 439 S. Union Street, 5th Floor, Lawrence, MA
01843 (together with its Affiliates (as defined below), hereafter referred to as
"NXSTAGE")

and

MEMBRANA GMBH, a company organized and existing under the laws of Germany having
offices at Ohder Str. 28, D-42289 Wuppertal, Germany (together with its
Affiliates, hereinafter referred to as "MEMBRANA")

WHEREAS, NxStage is engaged, inter alia, in the manufacture and sale of products
that deliver therapeutic renal care solutions including filters containing
membranes ("dialyzers");

WHEREAS, Membrana is engaged in the manufacture and sale of membranes for
various applications including without limitation, synthetic membranes for
hemodialysis;

WHEREAS, NxStage and Membrana are parties to that certain Supply Agreement with
an effective date of October 1, 2004 (the "OLD CONTRACT");

WHEREAS, Membrana and NxStage wish to replace the Old Contract in its entirety
with this Agreement;

WHEREAS, Membrana and NxStage wish to enter into this Agreement for the supply
of the hemodialysis membranes listed on Annex 1 (hereinafter referred to as the
"MEMBRANES"). Other types of membranes may be added to this list by the mutual
agreement of the parties;

NOW, THEREFORE, the parties agree as follows:

ARTICLE 1: SCOPE OF AGREEMENT

This Agreement replaces in its entirety the Old Contract and shall govern all
orders for Membranes provided to Membrana by NxStage from January 1, 2007 (the
"EFFECTIVE DATE") through December 31, 2016 (the "EXPIRATION DATE") unless
sooner terminated pursuant to this Agreement. Section 8.1 of the Old Contract
shall be superseded by Article 9 of this Agreement and Confidential Information
covered by such Section 8.1 shall be covered by Article 9 of this Agreement.
Purchases made prior to the Effective Date shall continue to be governed by the
Old Contract. Except as set forth in this Article 1, the Old Contract is
superseded in its entirety by this Agreement.

<PAGE>

ARTICLE 2: SPECIFICATIONS

Membranes will be manufactured according to the specifications set forth in
Annex 2 (the "SPECIFICATIONS"). NxStage shall have the right to periodically
make changes to the Specifications and/or add additional Specifications, subject
to the prior written consent of Membrana, which shall not be unreasonably
withheld. Changes in Specifications initiated by NxStage may result in changes
to pricing. NxStage shall consider in good faith all changes to the
Specifications proposed by Membrana, but shall not be required to accept such
proposed changes if (i) products containing membranes meeting the existing
Specifications are being sold by Membrana to third parties who are not being
required to move to new specifications, (ii) such proposed changes reduce, in
any way, the performance or manufacturability of the Membranes being supplied to
NxStage hereunder, as determined in the sole and reasonable discretion of
NxStage, or (iii) such proposed changes increase, in any way, the prices paid by
NxStage for Membranes hereunder. Further, even if none of the conditions set
forth in subsections (i), (ii) and (iii) occur, NxStage shall not be required to
accept such proposed changes until it has obtained all regulatory approvals
required to market products containing such modified Membranes in the
territories in which NxStage's products are then marketed. NxStage agrees that
it shall seek to obtain promptly any such required regulatory approvals. In the
event NxStage elects to purchase a new membrane type from Membrana, a signed
supplement will be added to this Agreement before the first shipment of such
membranes, detailing the pricing and membrane specifications, which shall be
agreed to in good faith by the parties hereto. Without limiting any of the
foregoing, Membrana shall make available to NxStage all high-flux membranes for
use in renal replacement or fluid overload therapies manufactured by Membrana
during the term of this Agreement, including without limitation membranes
developed after the Effective Date hereof, but excluding any such membranes
co-developed with a third party, except upon the written consent of such third
party, which Membrana shall use commercially reasonable efforts to obtain. In
the event NxStage elects to purchase a new membrane type from Membrana, a signed
supplement will be added to this Agreement before the first shipment of such
membranes, detailing the pricing and membrane specifications, which shall be
agreed to in good faith by the parties hereto. In determining the pricing for
any new membrane types, Membrana agrees to provide NxStage with competitive
pricing. All other terms of the Agreement will remain unchanged. If NxStage
declines to purchase a new membrane type introduced to it by Membrana, Membrana
shall be free to enter into an exclusive sales arrangement with a third party
for that membrane type.

ARTICLE 3: EXCLUSIVITY AND PRODUCT ORDERING

NxStage agrees to purchase from Membrana under this Agreement 100% of its
       requirements for blood contacting membranes used in dialyzers used with
       the NxStage System One or successor NxStage products. NxStage further
       agrees that Membrana shall have the right of first refusal with respect
       to the supply of membranes for other products used with the NxStage
       System One or successor products. In the event Membrana supplies such
       membranes, a separate agreement will be entered into by the parties to
       govern such sales.

3.1    NxStage shall submit purchase orders for Membranes at least [**] weeks
       prior to the desired shipment date. Membrana shall accept within [**]
       days of receipt of the applicable purchase order through a written order
       confirmation, and timely supply all purchase orders

                                      -2-
<PAGE>

       that are consistent with NxStage's then-current accepted Forecast (as
       defined in Section 6.3 below) and are in compliance with this Agreement.

3.2    Without limiting any other rights of NxStage hereunder, if Membrana
       cannot meet NxStage's volume requirements for any reason, other than due
       to a Force Majeure Event or due to breach of this Agreement by NxStage,
       and NxStage has placed valid purchase orders for such Membranes, Membrana
       will reserve production capacity for NxStage according to the ratio
       between [**].

3.3    Membrana shall use commercially reasonable efforts to accept and timely
       supply all orders in excess of NxStage's forecasted amount for the period
       or requesting delivery in less than [**] weeks from the order date, and
       shall notify NxStage in writing if Membrana anticipates that it will not
       be able to satisfy such orders by the delivery dates indicated.

3.4    NxStage shall duly examine all deliveries of Membrane bundles received
       for any apparent defects. Deviations with regard to the color shade of
       the Membranes shall not be deemed to be defects unless they lead to any
       deterioration in the quality or marketability (from NxStage's customers'
       perspectives) of the products made therefrom. NxStage shall notify
       Membrana of any defects discovered in writing within [**] months after
       the respective installment of Membranes has been received; provided that
       in the case of hidden defects, notice of defects shall be given by
       NxStage immediately after discovery, but no later than [**] years after
       the date of delivery of the Membranes (the "Membrane Expiration Date").
       In its notice, NxStage shall specify the quantity found defective, the
       corresponding invoice, packing units, fabrication numbers and production
       days of the Membrane bundles in question. NxStage makes no representation
       that it will inspect all Membranes delivered. Membrana understands that
       it is fully responsible for ensuring that its Membranes meet the
       Specifications. NxStage agrees that Membrana shall not be responsible for
       defects to Membranes caused directly by NxStage's (i) manufacturing
       processes; (ii) storage of Membranes in unsuitable conditions; or (iii)
       negligence or willful misconduct. Any claims by NxStage relating to
       defects in the Membranes not made within the timeframes described in this
       Section 3.4 shall be deemed waived provided, however, that any obligation
       of Membrana to provide indemnity under Section 10 shall apply to claims
       brought after the Membrane Expiration Date for incidents that occur prior
       to the Membrane Expiration Date where such claims are brought prior to
       the expiration of the applicable statute of limitations period or other
       applicable claim period contractually agreed between NxStage and the
       party bringing the claim, whichever occurs first.

3.5    For all timely claims, Membrana shall reimburse NxStage for the cost of
       [**] and shall replace all out--of-Specification Membranes not yet
       incorporated into finished product if requested by NxStage in lieu of a
       refund for such Membranes pursuant to Article 8. In addition, regardless
       of whether the limits described in Article 8 are met by payments made
       pursuant to the immediately preceding sentence, Membrana shall reimburse
       NxStage for all

                                      -3-
<PAGE>

       recall expenses incurred by NxStage pursuant to a recall under the
       supervision of a government agency, whether voluntary or involuntary, and
       relating to products incorporating out-of-Specification Membranes to the
       extent that such Membranes are the direct cause of the recall, up to [**]
       for the out-of-Specification Membranes.

ARTICLE 4: PRICES/PAYMENT

4.1    The parties agree to pricing as described in the sections that follow and
       agree that allowable adjustments to price will include: NxStage annual
       chronic Therapy Average Sales Price ("TASP", as such term is hereafter
       defined), actual annual fiber volume purchased, and Euro to US dollar
       exchange rates. Beginning in 2007 and annually thereafter, NxStage will
       provide a forecast of the volume of Membranes that it will purchase for
       the next calendar year by [**] and a forecast of the expected TASP for
       the next calendar year (an "Annual Forecast"). For convenience of
       invoicing and payments over 2008 and subsequent years, NxStage and
       Membrana will use the Annual Forecasts to mutually agree on an
       appropriate calculated invoice price for the next calendar year, using
       the pricing matrix below and the procedures detailed in this Article 4.
       The parties acknowledge that at the end of each year the invoiced price
       for Membranes shall be reconciled based on actual Membrane volumes
       purchased and actual TASP. Appropriate adjusting payments will be made
       between the parties, no later than March 1st following the end of the
       preceding calendar year, to reconcile the actual net price paid, per
       Section 4.4.3 below. For purposes hereof, "TASP" shall mean the average
       monthly total sales price paid by NxStage chronic customers prescribing
       monthly treatment with the NxStage System One, or its successor products.

4.2    The pricing for all Membranes ordered and received at NxStage during the
       period August 10, 2006 through December 31, 2006, and for the first
       shipment received in January, 2007, shall be [**] Euros per km. This
       price represents an equal split of the savings due to new Membrane
       pricing vs. applicable pricing from the Old Contract, retroactive to
       August 10, 2006.

4.3    For the calendar year 2007, the pricing shall be according to Figure 1
       below. This pricing matrix assumes a TASP of $[**] per patient per month
       and a baseline exchange rate as of the Effective Date of the contract of
       [**] US Dollars to 1 Euro for the same period.

Figure 1. Pricing for Calendar Year 2007

                                      -4-
<PAGE>

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------
   A. Annual      B. % of TASP for      C. Minimum Price       D. Base Euro
    Volume,        all Membranes            (Euro/km)         Price per km at
   ([**] Km)          purchased                                 TASP of [**]
                                                                 (US$/month)
--------------------------------------------------------------------------------
<S>               <C>                   <C>                   <C>
      [**]              [**]                  [**]                   [**]
--------------------------------------------------------------------------------
      [**]              [**]                  [**]                   [**]
--------------------------------------------------------------------------------
      [**]              [**]                  [**]                   [**]
--------------------------------------------------------------------------------
</TABLE>

       Note: The exchange rate of [**] US Dollars to 1.00 Euro is only used as
       the basis for establishing the percentages and prices listed in the
       table. This exchange rate is used to determine the applicable Base Euro
       pricing for each year and shall not be modified over the Term of this
       Agreement. Price adjustments for fluctuations in actual exchange rates
       will be handled as set forth in section 4.5 below.

       Note: All calculations taking place under this Section 4 will be carried
       out to 4 decimal places.

4.4    Pursuant to the Annual Forecasts and for calendar years beginning in
       2008, the parties shall create a new price matrix substantially
       equivalent to Figure 2 below. The price matrix shall be completed during
       the month of December of the prior year (beginning in December 2007) and
       shall incorporate the forecasted TASP for the forthcoming year in its
       derivation. The Base Euro Price (column D.) shall be calculated for each
       year using the % of TASP (Column B) provided that the price is not less
       than the "Minimum Price" (Column C). The values in Figure 2 assume a
       monthly therapy consisting of [**] treatments per month and [**] km of
       Membranes per treatment. As set forth in Section 4.4.3 below, changes to
       either of these baseline assumptions will require changes to Figure 2 and
       a formal amendment to this agreement. See Example A below for the
       completion of Column D for each year.

Figure 2.  Pricing for Calendar Years 2008 and Beyond

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------
  A. Annual      B. % of TASP for      C. Minimum Price       D. Base Euro
   Volume,        all Membranes            (Euro/km)        Price per km at
  ([**] Km)         purchased                               treatment fee of
                                                             TBD (US$/month)
--------------------------------------------------------------------------------
<S>              <C>                   <C>                  <C>
    [**]               [**]                  [**]
--------------------------------------------------------------------------------
    [**]               [**]                  [**]
--------------------------------------------------------------------------------
    [**]               [**]                  [**]
--------------------------------------------------------------------------------
</TABLE>

       4.4.1    Once Figure 2 has been completed for the specific calendar year,
                i.e. once Column D. has been derived, the forecasted fiber
                volume shall be used to derive the invoice price for the
                forthcoming year using linear interpolation [**]. The invoice
                price shall be the same for all Membranes shipped in a

                                      -5-
<PAGE>

                calendar year. See Example D below for the specifics of linear
                interpolation.

Example A -- Calculation of Base Euro Price (Column D)
If the forecasted and agreed TASP is $[**], then the Base Euro Price is
calculated as follows:

Therapy definition: [**] treatments per month x [**] km per treatment = [**] km
per month

$[**]/US$[**]/Euro = Euro [**]

Euro [**] x % of TASP (as set based on Annual Volumes) / [**] km per month =
Base Euro Price

<TABLE>
<CAPTION>
Annual Volume:    TASP              % of TASP     Therapy       Base Euro Price
-------------------------------------------------------------------------------
<S>               <C>               <C>           <C>           <C>
[**] Km           Euro [**]    x    [**]%  /      [**] km/month =     [**]
    ------------------     ---------    -----------------------------
[**] Km           Euro [**]    x    [**]%  /      [**] km/month =     [**]
    -------------------    ---------    ------------------------------
[**] Km           Euro [**]    x    [**]%  /      [**] km/month =     [**]
    -------------------    ---------    ------------------------------
</TABLE>

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------
  A. Annual      B. % of TASP for       C. Minimum Price     D. Base Euro
   Volume,         all Membranes           (Euro/km)        Price per km at
  ([**] Km)          purchased                               TASP of [**]
                                                              (US$/month)
-----------------------------------------------------------------------------
<S>              <C>                    <C>                 <C>
    [**]                   [**]                   [**]               [**]
-----------------------------------------------------------------------------
    [**]                   [**]                   [**]               [**]
-----------------------------------------------------------------------------
    [**]                   [**]                   [**]               [**]
-----------------------------------------------------------------------------
</TABLE>

Example B -- Calculation of Base Euro Price (Scenario 1) for Example Year
(Column D)
If the forecasted and agreed TASP is $[**], then the Base Euro Price is
calculated as follows:

Therapy definition: [**] treatments per month x [**] km per treatment = [**] km
per month

$[**]/US$[**]/Euro = Euro[**]

Euro[**] x % of TASP/[**] km per month = Base Euro Price

<TABLE>
Annual Volume:          TASP e          % of TASP      Therapy   Base Euro Price
--------------------------------------------------------------------------------
<S>            <C>                <C>            <C>             <C>
[**]           Euro [**]     x   [**]%  /        [**] km/month = [**]
    ----------------    ---------    ----------------------------
[**]           Euro [**]     x   [**]%  /        [**] km/month = [**]
    ----------------    ---------    ----------------------------
[**]           Euro [**]     x   [**]%  /        [**] km/month = [**]
    ----------------    ---------    ----------------------------
</TABLE>

                                      -6-
<PAGE>

Example B -- Continued -- Calculation of Base Euro Price for Example Year

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------
  A. Annual      B. % of TASP for       C. Minimum Price     D. Base Euro
   Volume,         all Membranes           (Euro/km)         Price per km at
  ([**] Km)          purchased                              treatment fee of
                                                            [**] (US$/month)
-------------------------------------------------------------------------------
<S>              <C>                    <C>                 <C>
     [**]                    [**]                   [**]                  [**]
-------------------------------------------------------------------------------
     [**]                    [**]                   [**]                  [**]
-------------------------------------------------------------------------------
     [**]                    [**]                   [**]                  [**]
-------------------------------------------------------------------------------
</TABLE>

Example C -- Calculation of Base Euro Price (Scenario 2) for Example Year
(Column D)
If the forecasted and agreed TASP is $[**], then the Base Euro Price is
calculated as follows:

Therapy definition: [**] treatments per month X [**] km per treatment = [**] km
per month

$[**]/US$[**]/Euro = Euro[**]

Euro[**] * % of TASP/[**] km per month = Base Euro Price

<TABLE>
<CAPTION>
Annual Volume:       TASP            % of TASP       Therapy     Base Euro Price
--------------------------------------------------------------------------------
<S>             <C>              <C>            <C>              <C>
[**]            Euro [**]   x    [**]% /        [**] km/month =  [**]
---------------------    --------    -----------     ------------
[**]            Euro [**]   x    [**]% /        [**] km/month =  [**]
    -----------------    --------    -----------     ------------
[**]            Euro [**]   x    [**]% /        [**] km/month =  [**]
    -----------------    --------    -----------     ------------
</TABLE>

HOWEVER, THE MINIMUM PRICE (COLUMN C) WILL BE APPLIED AS DEFINED BY SECTION 4.4

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------
  A. Annual      B. % of TASP for       C. Minimum Price     D. Base Euro
   Volume,        all Membranes           (Euro/km)         Price per km at
  ([**] Km)         purchased                               treatment fee of
                                                            [**] (US$/month)
-----------------------------------------------------------------------------
<S>              <C>                    <C>                 <C>
     [**]                    [**]                   [**]                [**]
-----------------------------------------------------------------------------
     [**]                    [**]                   [**]                [**]
-----------------------------------------------------------------------------
     [**]                    [**]                   [**]                [**]
-----------------------------------------------------------------------------
</TABLE>

         4.4.2    At the end of each year (beginning on December 31, 2007), the
                  parties will determine the difference between the invoice
                  price used for the then ending calendar year and the correct
                  invoice price for such year based on actual volumes purchased
                  and the actual TASP recorded for the year, applying the same
                  price to all Membranes shipped during the calendar year. Such
                  interpolation using the actual volumes purchased must be
                  applied to the pricing matrix for the just-completed year,
                  using the actual TASP and volumes to establish the fixed price
                  to be paid for that year. See Example D below for the
                  specifics of linear interpolation.

Example D -- Linear Interpolation

                                      -7-
<PAGE>

Referring to pricing table for 2007; if actual volume is [**] km then the
interpolated actual price would be:

[**]

The difference between the invoice price applied during the calendar year and
the actual price will be rebated to the appropriate party by March 1 of each
year.

         4.4.3    From time to time new bundle configurations (km/tx) and/or
                  treatment protocols based on less than [**] treatments per
                  month may be introduced. Once such alternative treatment
                  protocols reach [**]% or more of NxStage's total chronic
                  treatment sales, the parties shall agree upon the calculations
                  to be used in these situations it being understood that these
                  situations will be handled in an analogous fashion to the
                  calculations stated in this Section 4.1 to arrive at
                  appropriate base prices.

4.5 QUARTERLY EXCHANGE RATE ADJUSTMENT

All prices in this Agreement are in Euro unless otherwise stated. Foreign
exchange risk shall not affect the net invoice prices set forth in this Article
4 so long as the exchange rate between the US dollar and the Euro remains within
the range of 1 Euro to US$ [**] to US$ [**]. Exchange rate exposure sharing will
be calculated and applied quarterly using the average of published U.S. Federal
Reserve Board monthly figures (month 1 + month 2 + month 3)/3) for the calendar
quarter. The monthly exchange rate figure is currently accessible at
http://www.federalreserve.gov/releases/g5/, however if not available at that
address, the monthly exchange rate may be obtained directly from the U.S.
Federal Reserve Board. If the exchange rate goes outside the range of 1 Euro to
US$ [**] to US$ [**], then Membrana and NxStage will [**] the amount by which
the average published exchange rate differs from US$1.29 per Euro.
Notwithstanding the published exchange rate, for purposes of calculating the
risk sharing amount under this Article 4.3, the exchange rate value to be used
by the parties shall never be lower than US$ [**] to 1.00 Euro nor higher than
US$[**] to 1.00 Euro. For illustration purposes only, examples are set forth
below:

All adjusting payments to be made under this article 4.5 shall be made to the
receiving party in Euro and shall be converted to Euro at the quarterly average
exchange rate as defined here where necessary.

Example E -- Quarterly Exchange Rate Adjustment -- Scenario 1

                                      -8-
<PAGE>

Given an invoice price of Euro [**] for the calendar year (based upon [**] km
annual volume and linearly interpolated as in Example D) and a quarterly average
exchange rate of US$ [**] per Euro, then the currency risk sharing adjustment
will be as follows:

Risk-Shared Currency Exchange Rate:

($1.29 + $[**]  = [**] $/ Euro

Actual NxStage Price Paid in US$

Euro [**]/ Km x $[**] = $[**] / km

Currency-Adjusted NxStage Price in $US

Euro [**] / km x $[**] = $[**] / km

Net adjusting payment due to NxStage = $[**] - $[**] = $[**] / km

Net adjusting payment due to NxStage in Euros = $[**]) = [**] Euros / km

Example F -- Quarterly Exchange Rate Adjustment -- Scenario 2

Given an invoice price of Euro [**] for the calendar year (based upon [**] km
annual volume) and a quarterly average exchange rate of US$ [**] per Euro, then
the currency risk sharing adjustment will be as follows:

Risk-Shared Currency Exchange Rate:

($1.29 + $[**] = [**] $/Euro

However, the agreed exchange rate limit for risk sharing is $[**] to the Euro,
therefore the risk-shared exchange rate will be calculated as follows:

($1.29 + $[**]= [**] $/Euro

Actual NxStage Price Paid in US$

Euro [**] / Km  x $[**] = $[**] / km

Currency-Adjusted NxStage Price in $US

                                      -9-
<PAGE>

Euro [**] / km x $[**] = $[**] / km

Net adjusting payment due to Membrana = $[**] - $[**] = $[**] / km

Net adjusting payment due to Membrana in Euros = $[**] = [**] Euros / km

Example G -- Quarterly Exchange Rate Adjustment -- Scenario 3

Given an invoice price of Euro [**] for the calendar year (based upon [**] km
annual volume) and a quarterly average exchange rate of US$ [**] per Euro, then
the currency risk sharing adjustment will be as follows:

Risk-Shared Currency Exchange Rate:

 ($1.29 + $[**] = [**] $/Euro

However, the agreed exchange rate limit for risk sharing is $[**] to the Euro,
therefore the risk-shared exchange rate will be calculated as follows:

($1.29 + $[**] = [**] $/Euro

Actual NxStage Price Paid in US$

Euro [**]/Km  x $[**] = $[**] / km

The calculated Currency-Adjusted NxStage Price in $US

Euro [**] / km x $[**] = $[**] / km

The calculated Net adjusting payment due to NxStage = $[**] - $[**] = $[**] / km

However, the Minimum Price from column C of Figure 1, linearly interpolated to
an annual volume of [**] km will apply in this case.

The Currency-Adjusted NxStage Price in $US

Euro [**] x $[**] = $[**] / km

Net Adjusting payment due to NxStage = $[**] = $[**] / km

4.6 If NxStage fails to purchase a minimum of [**] km of Membranes in a calendar
year (the "BASE AMOUNT"), Membrana may terminate this Agreement upon 45 days'
written notice, provided that NxStage shall have the opportunity to purchase the
shortfall

                                      -10-
<PAGE>

amount, by submitting a purchase order for such volume during this 45 day
period. In the event of a Change of Control of NxStage (as defined below), the
Base Amount for the successor or acquirer shall be the higher of (i) the Base
Amount stated above, or (ii) [**] percent ([**]%) of the amount of the highest
past volume of Membranes purchased by NxStage in any calendar year of this
Agreement, which shall be annualized from the intervening months in the event
that a Change of Control happens prior to the conclusion of the first calendar
year (the "New Base Amount"). In addition to Membrana's other available
remedies, if the successor or acquirer of NxStage fails to purchase the New Base
Amount, the successor or acquirer will be required to purchase the shortfall
amount by submitting a purchase order for such volume within 45 days of the end
of the calendar year in which the New Base Amount was not achieved.
Notwithstanding the foregoing, the successor or acquirer of NxStage will not be
held liable for market forces or other factors outside of its control that drive
its requirements below the New Base Amount. In such an event Membrana and the
successor or acquirer of NxStage will agree upon an appropriate volume for the
New Base Amount in good faith.

4.7 If Membrana's actual direct material and utilities cost to manufacture
Membranes increases Membrana's cost to manufacture Membranes for NxStage by more
than [**]% after the Effective Date, then Membrana may, no more than [**] per
annum, and no more than [**] times over the term of this Agreement, propose to
raise the Membrane prices by the amount necessary to reflect only such direct
material or utilities costs increases subject to section 13.1 below. The parties
will discuss and agree to price increases in good faith.

4.8 Payments for all Membranes shall be due and payable by NxStage within [**]
days from the date of shipment of the Membranes. Membrana shall have the option
to change the payment terms if, in Membrana's reasonable discretion, NxStage
experiences a material adverse change in creditworthiness such as a decline in
credit rating applied by a third-party rating agency or repeatedly making late
payments for product.

4.9 Time is of the essence with regard to payments for Membranes. Late payments
shall bear interest at the lower of [**]% per month or the maximum amount
allowable under applicable law. In addition, late payments on undisputed
invoices that carry over the end of a calendar quarter shall automatically incur
a special administrative charge of [**]% of the past due balance of such late
payments.

4.10 From time to time, the parties shall work together on agreed upon joint
projects to identify and implement cost saving measures related to logistics.
Any savings that are

                                      -11-
<PAGE>

realized through these joint efforts shall be shared fairly between the parties
based upon each party's contribution to the project irrespective of whether the
implementation occurs at Membrana or NxStage's facilities.

ARTICLE 5: CAPACITY INSTALLATION

If, during the term of this Agreement, Membrana's capacity becomes insufficient
to meet NxStage's Membrane requirements, Membrana will consider adding
additional capacity and NxStage shall in good faith consider assisting Membrana
in obtaining the capital necessary to fund such additional capacity. Any capital
assistance provided by NxStage shall be returned to NxStage through price
decreases or such other terms agreed upon by the parties prior to NxStage
providing capital assistance. NxStage shall also consider agreeing to guaranteed
minimum volumes to assist Membrana in obtaining the capital necessary to fund
increased capacity. All additional capacity funded with NxStage assistance shall
be dedicated to supplying NxStage requirements on a first priority basis until
the capital assistance is repaid. Nothing herein shall limit Membrana's
obligation to supply Membranes to NxStage hereunder consistent with NxStage's
then-current forecasted requirements pursuant to Section 6.3.

ARTICLE 6: CONDITIONS

6.1    The resale of Membrane bundles in the form purchased by NxStage under
       this Agreement shall require Membrana's prior written consent.

6.2    Delivery of Membranes shall be free carrier (as defined in Incoterms
       2000) at Membrana's facility in Wuppertal, Germany. As soon as the
       Membranes leave Membrana's facility or are made available to NxStage for
       shipping, all transport risks shall pass to NxStage. A delivery period or
       a delivery date shall be deemed to have been adhered to if the goods have
       left Membrana's facility in Wuppertal, Germany by the expiry of the
       delivery period. Without limiting its obligations to fulfill all accepted
       purchase orders, Membrana shall be entitled to effect partial deliveries
       and to invoice for each such partial delivery, as far as a partial
       delivery is tolerable for NxStage. Membrana may deliver against any
       accepted purchase order up to [**]% more or less than the quantity
       ordered. The quantity actually delivered will be invoiced.
       Notwithstanding the foregoing, the parties agree that the preceding
       sentence shall not impact any of the percentages set forth in Sections
       6.5 and 6.6 hereof, and that in determining the percentages set forth in
       Sections 6.5 and 6.6 hereof, the parties shall calculate quantities of
       Membranes actually delivered compared to quantities ordered under NxStage
       accepted purchase orders.

6.3    Each month, NxStage shall provide Membrana with a rolling [**] month
       forecast (the "Forecast") with the first [**] months being a binding
       order. If Membrana produces Membranes in reliance on any of these binding
       portions of a forecast, NxStage agrees it

                                      -12-
<PAGE>

       will purchase those quantities of Membranes within [**] months of the
       date of the relevant forecast. Notwithstanding the foregoing, NxStage
       intends that the other [**] months of the forecast shall be nonbinding
       and that such months shall only be used by Membrana for planning
       purposes.

6.4    Shipment dates confirmed by Membrana are the dates ex warehouse
       Wuppertal, Germany.

6.5    Notwithstanding the foregoing, in the event that more than [**]% of
       NxStage's accepted purchase orders over any [**]-month period are not
       shipped within [**] days of the agreed upon shipment date, NxStage shall
       have the right to source the unavailable quantities from a third party
       and such volumes shall count towards the Base Amount and the volumes
       necessary to achieve certain pricing under Article 4.1, without penalty;
       provided that, in the case of a Force Majeure Event, such volumes shall
       not count towards the volumes necessary to achieve certain pricing under
       Article 4.1. If the cost of obtaining Membranes from another source is
       higher than the Membrane prices set forth herein, other than in the case
       of a Force Majeure Event, Membrana shall reimburse NxStage for the
       difference between the [**] and the [**] paid by NxStage hereunder;
       provided that Membrana shall have the [**], on behalf of NxStage, and to
       [**], upon the prior written consent of NxStage, which shall not be
       unreasonably withheld. Membrana understands that, in such event, time
       will be of the essence, and that Membrana must [**] thereof in order to
       preserve its rights of [**] under this Section 6.5. Once Membrana is able
       to supply the shortfall amount, and to meet 100% of NxStage's
       then-forecasted requirements, on a go-forward basis, NxStage shall resume
       purchasing 100% of its requirements from Membrana, except to the extent
       NxStage is then contractually prohibited from so doing by any third party
       from whom Membranes were purchased pursuant to the terms hereof.

6.6    In the event that (i) more than [**]% of NxStage's accepted purchase
       orders over any [**] month period (which months need not be consecutive)
       in the same [**] month period are not shipped within [**] days of the
       agreed upon shipment date, other than due to a Force Majeure Event, or
       (ii) more than [**]% of NxStage's accepted purchase orders over any (A)
       [**] consecutive months over the term of this Agreement, or (B) [**]
       month period, which months need not be consecutive, over the term of this
       Agreement, are not shipped within [**] days of the agreed upon ship date,
       other than due to a Force Majeure Event, or (iii) more than [**]% of
       NxStage's accepted purchase orders over any consecutive [**] month period
       over the term of this Agreement are not shipped within [**] days of the
       agreed upon ship date, due to a Force Majeure Event, then, in each case,
       the Base Amount requirements of Section 4.6 and the exclusivity
       requirements of Section 3 shall be terminated, and NxStage shall be free
       to obtain Membranes from another source thereafter (hereinafter
       collectively referred to, in each case, as an "Exclusivity Termination
       Event"), without liability. Following a Change of Control of Membrana (as
       defined below), in addition to the foregoing terms, the successor or
       acquirer of Membrana shall also pay to

                                      -13-
<PAGE>

       NxStage, in any of the scenarios set forth in subsections (i) and (ii)
       above, damages equal to [**] the Membrane Price for that volume of
       Membranes equal to NxStage's forecasted requirements for the [**], on an
       annualized basis, for the period of [**]. Any payments required pursuant
       to the preceding sentence must be made within [**] days of the date on
       which such payment is triggered.

6.7    In addition to the agreed prices, NxStage must pay any applicable
       statutory value-added or turnover tax. All other fees and taxes relating
       to NxStage's purchase of Membranes hereunder, which fees and taxes which
       were not known at the time of purchase, shall be borne by NxStage.
       Retention of due payments or offsetting shall be possible only on the
       basis of claims by NxStage which have been the subject of non-appealable
       court decisions or that have been acknowledged and agreed to by Membrana
       in writing.

ARTICLE 7: QUALITY DATA & TECHNICAL & SCIENTIFIC SUPPORT, REGULATORY MATTERS

7.1    Membrana shall provide NxStage with each shipment of Membranes the 'QC
       Data List' and the 'Attachment to QC-Specification' as shown by example
       in Annex 3. This shall include, among other things, a certification that
       the Membranes meet the Specification, and that the Membranes have been
       manufactured in accordance with applicable laws and regulations.

7.2    Membrana shall provide reasonable assistance to NxStage in connection
       with all regulatory filings made by NxStage or its affiliates relating to
       products incorporating the Membranes supplied by Membrana. Membrana,
       however, shall not be liable for any damages resulting from the given
       technical advice or the provided assistance.

7.3    NxStage and its representatives and affiliates shall have the right upon
       a minimum of [**] days' prior written notice to Membrana, during regular
       business hours, to audit Membrana's facilities where the Membranes are
       manufactured, packaged and stored and to make any further examination
       reasonably necessary to ascertain compliance with the Membrane
       Specifications.

7.4    Membrana shall give NxStage prompt notice if Membrana becomes aware of
       any defect or condition which in any way alters the Membrane
       Specifications or the quality of any of the Membranes supplied.

7.5    Membrana shall trace and maintain records regarding the source and lot
       number of each Membrane shipment for a period of [**] years after
       shipment of the Membranes to which the records pertain. These records
       shall be delivered to NxStage upon NxStage's request or upon the
       termination of this Agreement.

7.6    Membrana shall promptly notify NxStage of the occurrence of any changes
       in regulatory status related to its production of Membranes and of the
       outcome of any regulatory

                                      -14-
<PAGE>

       inspections which suggest a material weakness or deficiency in the
       quality of Membrana's Membrane manufacturing processes, documentation or
       facilities.

ARTICLE 8: LIMITED WARRANTY, LIABILITY AND DEFECTIVE MEMBRANES

8.1    NxStage and Membrana each hereby represent and warrant as follows:

       8.1.1     It is a corporation duly organized, validly existing and in
                 good standing under the laws of the jurisdiction of its
                 incorporation and has the full corporate power and authority to
                 enter into this Agreement and perform its agreements and
                 covenants to be performed hereunder.

       8.1.2     The execution and delivery of this Agreement and its
                 performance of the covenants and agreements hereunder have been
                 duly authorized by all necessary corporate action and, when
                 executed and delivered, shall be valid and binding upon it.

       8.1.3     Neither the execution and delivery of this Agreement nor the
                 performance by it of the transactions contemplated herein will
                 violate any provision of its certificate of incorporation or
                 bylaws or any rule, law, regulation, judgment, decree or other
                 order of any court, government, or governmental agency or
                 instrumentality, or conflict with or result in any breach of
                 any of the terms of, or the creation or imposition of any
                 charge or encumbrance pursuant to, any contract or agreement to
                 which it is a party or by which it, or any of its assets and
                 properties are bound.

Membrana warrants that the Membranes shipped to NxStage pursuant to this
Agreement shall meet the Specifications. EXCEPT AS SET FORTH IN THIS ARTICLE 8,
MEMBRANA EXPRESSLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED INCLUDING THE WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. EXCEPT AS SET FORTH IN ARTICLE 10 AND IN SECTION 3.5, IN THE EVENT OF
ANY CLAIMED OR ACTUAL BREACH OF WARRANTY, NXSTAGE'S SOLE AND EXCLUSIVE REMEDY IS
THE [**] OR [**]. EXCEPT AS SET FORTH IN ARTICLE 10, ARTICLE 6, OR, WITH RESPECT
TO RECALL EXPENSES, SECTION 3.5, OR IN THE CASE OF WILFUL REFUSAL TO SUPPLY
MEMBRANES WITHIN FORECAST ON A TIMELY BASIS (NOT DUE TO A FORCE MAJEURE EVENT),
MEMBRANA'S TOTAL LIABILITY UNDER THIS AGREEMENT REGARDLESS OF THE NATURE OF THE
CLAIM SHALL NOT EXCEED [**] TIMES THE INVOICE PRICE OF THE MEMBRANES THAT GAVE
RISE TO THE CLAIM. EXCEPT AS SET FORTH IN ARTICLE 10, IN NO EVENT SHALL EITHER
PARTY BE LIABLE FOR ANY INCIDENTAL, CONSEQUENTIAL, STATUTORY, PUNITIVE,
EXEMPLARY OR OTHER INDIRECT DAMAGES, INCLUDING, WITHOUT LIMITATION, LOSS OF
PROPERTY,

                                      -15-
<PAGE>

AND LOSS OF BUSINESS OR PROFITS OR OTHER ECONOMIC LOSSES, REGARDLESS OF THE
NATURE OF THE CLAIM OR THEORY OF RECOVERY.

Membrana shall not be liable for minor violations of the Agreement which do not
result in material harm to NxStage or physical injury to a person (it being
specifically understood without limitation that the delivery of
out-of-Specification Membranes shall constitute a major violation of the
Agreement), unless such minor violations are the result of Membrana's or its
agents' or affiliates' gross negligence or willful misconduct. Without limiting
the terms of this Agreement, including without limitation Article 3, the parties
agree to share adverse product yield impacts as measured by NxStage's Fiber leak
rate in NxStage's filter manufacturing plant, as. follows: Membrana will credit
NxStage [**] times the invoice price of Membrane bundles rejected over [**]% of
Membrane bundles incorporated by NxStage in dialyzers in a calendar month if
such fiber leaks are proven to be present in the Membranes as shipped by
Membrana. NxStage will supply Membrana with regular leak rate updates and
whenever a leak rate of over [**]% is reached. Membrana may request samples of
defective bundles prior to payment of a leak rate claim to confirm the accuracy
of the claim and to assist in investigations. Any payments to be made pursuant
to the foregoing paragraph shall be calculated and made [**] at the end of each
calendar [**]. For the avoidance of doubt, this Section is not intended to cover
fiber leaks incorporated in finished goods dialyzers.

ARTICLE 9: CONFIDENTIALITY, INTELLECTUAL PROPERTY, INFRINGEMENT MATTERS

9.1    NxStage shall keep strictly confidential any information disclosed by
       Membrana during the term of this Agreement or that was disclosed under
       the Old Contract which is confidential by nature or expressly marked as
       confidential, and Membrana will keep strictly confidential all
       information disclosed by NxStage during the term of this Agreement or
       that was disclosed under the Old Contract which is confidential by nature
       or expressly marked as confidential. Without limiting the foregoing,
       Membrana shall treat NxStage purchase orders, forecasts, and complaint
       investigation information as strictly confidential, especially prices,
       quantities and Membrane Specifications. The Parties' obligations to keep
       information confidential shall survive for [**] years following the
       termination of this Agreement.

For purposes of this Agreement, confidential information shall not include:

         -        Information, which was, or becomes, in the public domain
                  through no fault or action of the non-disclosing party;

         -        Information which was already known by the non-disclosing
                  party, as shown by its written records;

         -        Information which becomes known by the non-disclosing party
                  from a third party not under an obligation of confidentiality
                  to the disclosing party; or

                                      -16-
<PAGE>

         -        Information which is independently developed by the
                  non-disclosing party.

         The parties further agree that the terms of this Agreement shall be
         treated as confidential; provided that either party may disclose the
         terms hereof if required by law, including without limitation, pursuant
         to the requirements of United States Securities laws.

9.2    All ideas, developments and inventions which are made or conceived by
       Membrana jointly with representatives of NxStage during the term of this
       Agreement relating to dialysis equipment but excluding membranes shall be
       the sole and exclusive property of NxStage. All ideas, developments and
       inventions made or conceived by NxStage jointly with representatives of
       Membrana during the term of this Agreement relating to membranes
       including membrane manufacturing technology but excluding dialysis
       equipment shall be the sole and exclusive property of Membrana. In the
       event that a joint patent application is filed based on this Section 9.2,
       the parties will seek to negotiate in good faith an exclusive license
       agreement that will state which claims each party will have exclusive
       freedom to practice should the patent be granted; it being understood
       that such license shall contemplate that those claims relating to
       dialysis equipment shall be licensed exclusively to NxStage and those
       claims relating exclusively to membranes and membrane manufacturing
       technology shall be licensed exclusively to Membrana.

9.3    Membrana represents and warrants that, as of the Effective Date, it is
       not aware of any third party patent rights which are infringed by
       Membranes supplied to NxStage hereunder in the condition in which they
       are shipped to NxStage. In the event that such a right is asserted
       against either party, however, the respective party shall immediately
       inform the other party and both parties shall discuss subsequent actions.

         a)       If after due evaluation Membrana or NxStage decides to reduce
                  or stop the supply or use of Membranes in compliance with such
                  assertion, then Membrana will buy back from NxStage up to [**]
                  months of unused inventories of Membranes, as the case may be,
                  at the same price as NxStage has paid for Membranes.

         b)       If the parties agree to continue the supply and use of
                  Membranes in spite of such an assertion, they shall jointly
                  organize their defense and shall agree on a fair sharing of
                  costs required for an appropriate defense.

9.4      NxStage represents and warrants that, as of the Effective Date, it is
         not aware of any third party patent rights which are infringed by the
         dialyzers with the incorporation of the Membranes supplied to NxStage.
         In the event that such a right is asserted against either party,
         however, the respective party shall immediately inform the other party
         and both parties shall discuss subsequent actions.

                                      -17-
<PAGE>

         a)       If after due evaluation Membrana or NxStage decides to reduce
                  or stop the supply or use of Membranes in compliance with such
                  assertion, then NxStage will buy from Membrana up to [**]
                  months of unused inventories of Membranes, as the case may be,
                  at then-current pricing, to the extent quantities of inventory
                  are consistent with any then-current forecasts.

         b)       If the parties agree to continue the supply and use of
                  Membranes in spite of such an assertion, they shall jointly
                  organize their defense and shall agree on a fair sharing of
                  costs required for an appropriate defense.

ARTICLE 10: INDEMNIFICATION

10.1   Each party ("the Indemnifying Party") agrees to indemnify and hold the
       other party (the other party and its affiliates and the officers,
       employees and directors of the other party and its affiliates,
       collectively hereinafter referred to as the "Indemnified Party") harmless
       from any and all third party claims, damages, costs and expenses that may
       be claimed or asserted against the Indemnified Party, arising out of the
       negligence of the Indemnifying Party in performing its obligations
       hereunder or the breach of the Indemnifying Party of any terms hereunder,
       or the supply of a defective product or component (including, in the case
       of NxStage, its dialyzers) by the Indemnifying Party. The obligation of
       the Indemnifying Party to indemnify the Indemnified Party pursuant to
       this Section shall be conditioned upon the Indemnified Party giving
       reasonably prompt notice of any such claim for indemnification to the
       Indemnifying Party, and giving the Indemnifying Party authority to
       conduct the defense of any action in its sole discretion including
       deciding on settlement of any action; provided, however, that the
       Indemnified Party may retain additional counsel at its own expense and
       participate in any such litigation.

10.2   In order to discharge the obligations set forth in Section 10.1, Membrana
       and NxStage each agree to obtain and keep in force during the term of
       this Agreement, product liability insurance with a limit of liability of
       not less than $5,000,000. The insurance policies evidencing such
       insurance shall be endorsed to name NxStage and Membrana, as the case may
       be, as an additional insured and provide that the insurer will endeavor
       to provide written notification to the other party by the insurer of not
       less than thirty (30) days prior to cancellation, expiration or material
       modification of such insurance. A certificate of insurance from
       Membrana's and NxStage's insurers evidencing compliance with the
       requirements of this Section shall be given to NxStage and Membrana,
       respectively, upon the execution of this Agreement.

ARTICLE 11: TRADEMARK LICENSE

       NxStage shall co-brand any products it sells containing Membrana's
       Membranes with Membrana's trademark(s) related to such Membranes. Product
       containing PUREMA(R) Membranes shall include the Purema(R) trademark on
       brochures and publications as set

                                      -18-
<PAGE>

       forth in the trademark license agreement attached hereto as Annex 4 (the
       "Trademark Agreement"). NxStage shall not be required to put the PUREMA
       mark on product labels where it is not reasonably practical to do so.

ARTICLE 12: APPLICABLE LAW AND JURISDICTION

12.1   This Agreement shall be governed and construed in accordance with the
       laws of the state of Delaware, USA. The United Nations Convention on
       Contracts for the International Sales of Goods and any related subsequent
       Conventions shall not apply to sales hereunder.

ARTICLE 13: MISCELLANEOUS PROVISIONS

13.1   NxStage shall have the right, at its option and expense, to have a third
       party audit Membrana's records regarding its increased costs pursuant to
       Section 4.7 above once a year. Membrana shall have the right, at its
       option and expense, to have a third party audit NxStage's records with
       respect to its Treatment Fees once a year. Third party auditors may only
       report whether the value of cost or fees declared by a party is correct
       or incorrect and, if incorrect, the amount of the difference. If an audit
       uncovers errors in the value of costs or fees claimed by either party,
       appropriate rebates or other payments will be made using the corrected
       values. Further, the party with the uncovered error, if such uncovered
       error exceeds $[**], shall bear the cost of the third party audit.

13.2   This Agreement constitutes the entire Agreement between the parties.

13.3   Amendments and/or supplements to this Agreement must be in writing signed
       by both parties.

13.4   If any of the provisions of this Agreement should be or become invalid,
       this shall in no way interfere with the validity of the other provisions.
       The parties to this Agreement shall then replace the invalid provision by
       a new provision which comes the closest possible to the spirit of the
       provision declared to be invalid. Neither party shall be entitled to any
       compensation in case that any of the provisions of this Agreement is or
       becomes invalid.

13.5   This Agreement is not assignable or transferable by either party except
       to its successor or the transferee of all or substantially all of said
       party's business and assets to which this Agreement relates, and shall be
       binding upon and inure to the benefit of the parties, their current and
       future Affiliates, and their successors and permitted assigns.
       "AFFILIATE" means any person or entity directly or indirectly
       controlling, controlled by or under common control with the party in
       question. Each party will cause its Affiliates, successors and assigns to
       abide by the terms and conditions of this Agreement. The parties
       specifically agree that if a majority of their ownership or dialysis
       assets or Membrane manufacturing capacity is acquired by any third party
       (a "Change of Control"), that such third party will

                                      -19-
<PAGE>

       be bound by this Agreement and shall be required to fulfill the
       obligations of its predecessor as though such third party was an original
       party hereto. Membrana agrees that the exclusivity obligations set forth
       herein shall only apply to a successor (or acquirer) of NxStage's
       business following a Change of Control with respect to Membranes used in
       dialyzers used with the NxStage System One, or a successor product, and
       not to any other dialyzers manufactured by such successor (or acquirer).

13.6   Except as otherwise set forth in this Agreement, if either party is in
       breach or violation of any term or condition contained in this Agreement
       other than breaches related to payments of invoices, the other party
       shall provide written notice of such alleged breach to the breaching
       party. The breaching party shall then have a reasonable time to cure such
       breach of no less than [**] days. If it does so in a timely manner, then
       such breach shall be of no further effect and the parties shall resume
       their performance of this Agreement. In the event the breach is not so
       timely cured, then the non-breaching party shall have the ability to
       terminate this Agreement upon 30 days prior written notice to the
       breaching party.

13.7   Neither party shall be liable to the other party for any actual or
       threatened Act of God, war, the public enemy, mobilization, riot, strike,
       lockout, drought, fire, flood, explosion, accident, shortage of raw
       materials, delays of carriers, embargoes, the acts or orders of
       governments or political subdivisions thereof, or any other contingency
       or cause beyond the reasonable control of the affected party, which
       prevents or materially hinders such party's performance under this
       Agreement (a "FORCE MAJEURE EVENT"). The party undergoing the Force
       Majeure Event will provide written notice to the other party of such
       event and shall also inform the other party in writing when the affected
       party is able to resume its performance under this Agreement.

This Agreement may be executed in one or more counterparts, each of which will
       be deemed to be an original, but all of which will constitute one and the
       same instrument.

                            [signature page follows]

                                      -20-
<PAGE>

IN WITNESS WHEREOF, the undersigned parties have caused their duly authorized
representatives to execute this Agreement as of the Effective Date.

NXSTAGE MEDICAL, INC.                           MEMBRANA GMBH

By: /s/ Jeffrey H. Burbank                      By: /s/ Ulf Seidel
    -----------------------------------------       ----------------------------
    Name: Jeffrey H. Burbank                        Name: Ulf Seidel
    Title: President & Chief Executive Officer      Title: VP Sales & Marketing
    Date: 1/4/07                                    Date: 05-01-07
    Place: Lawrence, MA                             Place: Wuppertal, Germany

                                                By: /s/ Anthony W. Mancusi
                                                    ----------------------------
                                                    Name: Anthony W. Mancusi
                                                    Title: Key Account Manager
                                                    Date: 1/5/2007
                                                    Place: Charlotte, NC

                                      -21-
<PAGE>

                                     Annex 1
                                    Membranes

Membrana's PUREMA(R) membranes as specified on Annex 2.

                                      -22-
<PAGE>

                                     Annex 2
                                 Specifications
                                   (attached)

                                      -23-
<PAGE>

<TABLE>
<CAPTION>
<S>              <C>                                      <C>  <C>     <C>              <C>              <C>

                                                                                        --------------------------
                                                                                        MEDICAL MEMBRANE
                                                                                        --------------------------

MEMBRANA                                                               DATA SHEET
UNDERLINING PERFORMANCE                                                PRELIMINARY

PUREMA(R)                                                              INTENDED USE:    HEMODIALYSIS

                                                                       SHEET NO.        084/0126/000      OF 06/06
CAPILLARY MEMBRANE                                                     SUPERSEDES       084/0126/000      OF 12/04
TYPE H

CHEMICAL COMPOSITION                                                                                   TEST REF.NO:
                 --------------------------------------------------------------------------------------------------
                 Polymer                                  Polyethersulfone
-------------------------------------------------------------------------------------------------------------------
PHYSICAL PROPERTIES
                 --------------------------------------------------------------------------------------------------
                 Wall thickness                           m               30      (mu)m                  701/017
                                                          d          +/-  5       (mu)m
                 --------------------------------------------------------------------------------------------------
                 Inner diameter                           m               200     (mu)m                  701/017
                                                          d          +/-  15      (mu)m
-------------------------------------------------------------------------------------------------------------------
MEMBRANE PERFORMANCE CHARACTERISTICS
                 --------------------------------------------------------------------------------------------------
                 [**]                                     [**]       [**]         [**]                   [**]
                 [**]
                 [**]
                 --------------------------------------------------------------------------------------------------
                 [**]                                                                                    [**]
                 [**]
                 [**]                                     [**]       [**]
                 [**]                                     [**]       [**]
-------------------------------------------------------------------------------------------------------------------
AVAILABLE MAKE-UP CONFIGURATIONS
                 --------------------------------------------------------------------------------------------------
                                                          Bundles (customer specified), with P.E.T.(R)
                 --------------------------------------------------------------------------------------------------

The information contained in this data sheet reflects the      m = mean value; d = deviation of the mean value;
company's knowledge and experience at the time of issue.       a)mmHg = 1.333 mber = 133.3 Pa
No guarantee can, however, be given as to its                  (R) = reg. trade mark
completeness. Neither must it be construed to embody any       P.E.T. = Performance Enhancing Technology
liability on the part of Membrana GmbH beyond the
company's "General Conditions of Sale".
For questions related to handling and manufacturing please     MEMBRANA GMBH
refer to our separate "Instructions for handling and           Oehder Strabe 28, D - 42289 Wuppertal, Germany
processing (PUREMA(R))".                                       Postal address: Postfach 20 01 51, D - 42201 Wuppertal
This product is delivered non-sterile.                         Phone  (+49) (202) 6099-1
                                                               Fax    (+49) (202) 60 70 296
                                                               www.membrane.com

                                                               A POLYPORE COMPANY
</TABLE>

                                      -24-

<PAGE>

<TABLE>
<CAPTION>
<S>              <C>                                      <C>  <C>     <C>              <C>              <C>

                                                                                        --------------------------
                                                                                        MEDICAL MEMBRANE
                                                                                        --------------------------

MEMBRANA                                                               DATA SHEET
UNDERLINING PERFORMANCE                                                PRELIMINARY

PUREMA(R)                                                              INTENDED USE:    HEMODIALYSIS

                                                                       SHEET NO.        084/0000/000      OF 12/04
CAPILLARY MEMBRANE                                                     SUPERSEDES       084/0000/000      OF 08/04
PRIMARY BUNDLES

------------------------------------------------------------------------------------------------------------------
BUNDLE DIMENSIONS                                                                                     TEST REF.NO:
                 ----------------------------------------- -------------------------------------------------------
                 Length                                    nominal value                                  [**]
                                                           [**]       [**]        mm
                 -------------------------------------------------------------------------------------------------
                 Diameter                                  nominal value                                  [**]
                                                           [**]       [**]        mm
                 -------------------------------------------------------------------------------------------------
                 Number of capillaries                     nominal value
                                                                                                          --------
                                                           [**]       [**]        mm
---------------------------------------------------------- ---------- --------------------------------------------

The information contained in this data sheet reflects the      d = deviation of the mean value;
company's knowledge and experience at the time of issue.       (R) = reg. trade mark
No guarantee can, however, be given as to its
completeness. Neither must it be construed to embody
any liability on the part of Membrana GmbH beyond
the company's "General Conditions of Sale".
This product is delivered non-sterile.                         MEMBRANA GMBH
                                                               Oehder Strabe 28, D - 42289 Wuppertal, Germany
                                                               Postal address: Postfach 20 01 51, D - 42201 Wuppertal
                                                               Phone  (+49) (202) 6099-1
                                                               Fax    (+49) (202) 60 70 296
                                                               www.membrane.com

                                                               A POLYPORE COMPANY
</TABLE>

                                      -25-

<PAGE>

                                     Annex 3
                         QC Data and Data List Examples

                                      -26-

<PAGE>

MEMBRANA
UNDERLINING PERFORMANCE

PUREMA(R) QC DATA LIST

DATE              28.11.2006
DELIVERY TO       NxStage GmbH & Co. KG
CONFIRMATION      0000011354
WEIGHT SPEC.      0080015502
INVOICE-NO.       007463019

PUREMA(R) CAPILLARY MEMBRANE                 TYPE: PUREMA H             [**]
                                             FIBERS/BUNDLE      :  [**]
                                             LENGTH/FIBERS (MN) :  [**]
                                             FINAL LENGTH ACCORDING TO CUSTOMERS
                                             SEPARATE SPECIFICATION
CRATE-NO.: 131536/2006255059-2006260077

<TABLE>
<CAPTION>
DATE     F-        JUL.           MEAN VALUE            SC         SC
TE       NO        DAY               UFR               CYTC       BSA

<S>      <C>       <C>            <C>                  <C>        <C>
SEP
12.      2085      06-255           [**]               [**]       [**]
13.                06-256           [**]               [**]       [**]
14.                06-257           [**]               [**]       [**]
15.                06-258           [**]               [**]       [**]
16.                06-259           [**]               [**]       [**]

16.      2086      06-259           [**]               [**]       [**]
17.                06-260           [**]               [**]       [**]
</TABLE>

QUALITY CONTROL MANAGEMENT

THIS QC DATA LIST HAS BEEN MADE BY ELECTRONIC DATA PROCESSING AND, THEREFORE,
HAS NOT BEEN SIGNED.

THIS QC DATA LIST HAS BEEN PREPARED WITH CARE AND TO THE BEST KNOWLEDGE AS PART
OF THE QUALITY ASSURANCE SYSTEM OF MEMBRANA GMBH. HOWEVER, IT DOES NOT RELIEVE
OUR CUSTOMERS OF THEIR OBLIGATION TO INSPECT THE GOODS UPON RECEIPT OR ESTABLISH
ANY WARRANTIES TO THIRD PARTIES TO WHOM IT MIGHT BE PASEED. NO ADDITIONAL
WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, IS LINKED HERETO.

                                                       MEMBRANA GMBH

                                                       Oehder Strabe 28
                                                       D - 42289 Wuppertal
                                                       Germany
                                                       Fon +49 (0) 2 02 60 99-0
                                                       Fax +49 (0) 2 02 60 57 15

                                                       www.membrane.com

Registered office: Wuppertal, Registry: Wuppertal Reg. 8 No. 9318

                                      -27-
<PAGE>

MEMBRANA
UNDERLINING PERFORMANCE

ATTACHMENT QC-SPECIFICATION

DATE              28.11.2006
DELIVERY TO       NxStage GmbH & Co. KG
CONFIRMATION      0000011354
WEIGHT SPEC.      0080015502
INVOICE-NO.       007463019

PUREMA(R) CAPILLARY MEMBRANE        TYPE: PUREMA H             UFR APP. 37

<TABLE>
<CAPTION>
ALMK/         PACK-           F-NO.      PROD.-       QTY         QTY OF        LENGTH      COMMER.
MATHR         NO.                        DATE         BUND.       FIBRES        IN MM       QTY./KM

<S>           <C>             <C>        <C>          <C>         <C>           <C>         <C>
04/131536     2006255059      2085       06255        [**]         [**]         [**]          [**]
                                         06256        [**]
              2006256060      2085       06256        [**]                                    [**]
              2006256061      2085       06256        [**]                                    [**]
              2006256062      2085       06256        [**]                                    [**]
              2006256063      2085       06256        [**]                                    [**]
                                         06257        [**]
              2006257064      2085       06257        [**]                                    [**]
              2006257063      2085       06257        [**]                                    [**]
              2006257066      2085       06257        [**]                                    [**]
                                         06258        [**]
              2006257067      2085       06257        [**]                                    [**]
              2006258068      2085       06258        [**]                                    [**]
              2006258069      2085       06258        [**]                                    [**]
              2006258070      2085       06258        [**]                                    [**]
              2006258071      2085       06258        [**]                                    [**]
                                         06259        [**]
              2006259072      2085       06259        [**]                                    [**]
              2006259073      2085       06259        [**]                                    [**]
              2006359074      2085       06259        [**]                                    [**]
              2006259075      2086       06259        [**]                                    [**]
                                         06260        [**]
              2006260076      2086       06260        [**]                                    [**]
              2006260077      2086       06260        [**]                                    [**]
</TABLE>

QUALITY CONTROL MANAGEMENT                             MEMBRANA GMBH

                                                       Oehder Strabe 28
                                                       D - 42289 Wuppertal
                                                       Germany
                                                       Fon +49 (0) 2 02 60 99-0
                                                       Fax +49 (0) 2 02 60 57 15

                                                       www.membrane.com

Registered office: Wuppertal, Registry: Wuppertal Reg. 8 No. 9318

                                      -28-
<PAGE>

                                     Annex 4
                Standard Trademark License and Quality Agreement

                                      -29-

<PAGE>

                    NONEXCLUSIVE TRADEMARK LICENSE AGREEMENT

THIS AGREEMENT ("Agreement"), is made effective as of January 1, 2007, by and
between Membrana GmbH, a corporation organized under the laws of Germany, whose
principal place of business is located at Ohder Stra(beta)e 28, D-42289
Wuppertal, Germany (hereinafter referred to as "Licensor"), and NxStage Medical,
Inc. a Delaware corporation whose principal place of business is located at 439
South Union Street, Lawrence, MA 01843 (hereinafter referred to as "Licensee").

WHEREAS, Licensor is the owner of the entire right, title and interest in and to
the trademark "PUREMA" (hereinafter referred to as the "Trademark") for
membranes, namely membranes for therapeutic purposes, and for modules equipped
with the aforesaid membranes for use in medical apparatus especially dialysers,
registered among others in International Class 10 among others in Germany (Reg.
No. 30362253), in the United States of America (Serial No. 76/563234) and as
International Registration (IR No. 844176). Licensor is producing and selling
membranes made from synthetic polymer under said Trademark (hereinafter referred
to as the "Goods");

AND WHEREAS Licensee sells dialyzers and is interested in using the Trademark
for dialyzers containing the Goods (hereinafter referred to as the "Contract
Products");

AND WHEREAS, Licensor and Licensee are parties to a Supply Agreement dated of
even date herewith (hereinafter referred to as the "Supply Agreement").

NOW, THEREFORE, in consideration of the mutual covenants of the parties and the
sum of One Dollar ($1) herewith paid by Licensee to Licensor, the receipt of
which is hereby acknowledged by Licensor, the parties hereby agree as follows:

1. License. Licensor grants to Licensee a non-exclusive, non-royalty bearing
right to use the Trademark under the common law and under the auspices and
privileges provided by the registrations described above, covering the same
during the term of this Agreement solely in connection with Contract Products.
The License hereby granted by Licensor shall include the right of Licensee to
use said Trademark on Contract Products as well as on the packaging for the
Contract Products and promotional, sales and advertising literature in
association with the Contract Products.

2. Trademark Usage: Licensee shall be obligated to affix or otherwise display
the Trademark on the Contract Products, except where it is not reasonably
practicable to do so, packaging for the Contract Products and on promotional,
sales and advertising literature in association with the Contract Products in a
form and manner in compliance with the standards and specifications as
prescribed by Licensor (see Appendix 1). Notwithstanding the foregoing, Licensee
shall not be obligated to affix or display the Trademark on such portions of the
Contract Products where it does not place its own trademarks and where it is not
reasonably practicable to do so. Licensee shall have no obligation to affix or
otherwise display the Trademark on any finished Contract Products in inventory
as of the Effective Date that do not already bear the Trademark, which shall be
no more than six (6) months worth of inventory..

To the extent possible and reasonable from a technical and logistical
standpoint, Licensee shall be obligated to attach a notice that the Trademark is
registered to Licensor. . This notice shall be made through use of the symbol
(R) and a footnote explaining that the Trademark is registered trademark of
Licensor.

                                      -30-
<PAGE>

3. Inspection. Licensee will permit duly authorized representatives of the
Licensor to inspect Contract Products and related promotional materials of
Licensee at Licensee's premises using the Trademark at all reasonable times, in
a reasonable manner, and upon reasonable advance notice, for the sole purpose of
and strictly limited to ascertaining or determining compliance with Paragraphs
1, 2 and 4 hereof.

4. Use of Trademark. Attached hereto as Exhibit A are representative samples of
Product literature and promotional materials, including Licensor's Trademark.
Licensee agrees that its use of the Trademark in future materials developed by
Licensee shall be consistent with the appearance and placement of the Trademark
in the materials attached hereto as Exhibit A. On June 1st of every year,
Licensee shall provide Licensor with a copy of all product literature and
promotional material bearing the Trademark. Licensor shall advise Licensee of
any issues with the appearance and placement of the Trademark in the materials.
If Licensor does not approve, Licensee shall work with Licensor to promptly
address the issues and amend the materials so that they are mutually
satisfactory. If June 1st does not fall on a business day, Licensee shall
provide the materials on the first business day following June 1st.

5. Extent of License. The license granted in this Agreement shall be
nonexclusive and may not be sublicensed or transferred by Licensee without
Licensor's prior written consent, provided, however, that Licensee shall have
the right to assign this Agreement without the consent of Licensor to its
successor or the transferee of all or substantially all of its business and
assets to which this Agreement relates, provided that this Agreement shall be
binding upon any successor or permitted assign. Licensor shall have the right to
use the Trademark and to license its use to any other designee. In the event of
any pre-approved assignment, transfer, or sublicense, this Agreement, and the
rights and obligations hereunder, shall be binding upon such assignee,
transferee or sublicensee. Licensor hereby warrants and represents to Licensee
that Licensor owns the entire right, title and interest in and to the Trademark,
and that Licensor has the unrestricted right to grant the license and otherwise
enter into this Agreement.

6. Third Party Infringement. In the event any third party violates Licensor's
right, title or interest in the Trademark, Licensee shall reasonably cooperate
with Licensor in Licensor's defense of its rights at Licensor's expense.
Licensee shall notify Licensor of any violations of Licensor's right, title or
interest in the Trademark of which Licensee is aware. Licensor has the exclusive
right to prosecute and defend all suits or proceedings before governmental
agencies which involve in any way validity of, title to, or infringement of the
Trademark.

7. Termination.

      a. Except as otherwise provided herein, this Agreement shall remain in
full force and effect. This Agreement will be terminated: (i) at the will of
either party upon not less than six (6) months advance written notice to the
other party; (ii) by Licensor upon written notice if Licensee makes any
assignments of assets or business for the benefit of creditor, or a trustee or
receiver is appointed to conduct its business or affairs, or it is adjudged in
any legal proceeding to be either in voluntary or involuntary bankruptcy; or
(iii) immediately upon the expiration or termination of the Supply Agreement. In
the event this Agreement is terminated by Licensor pursuant to this subparagraph
(a), Licensee shall be able to continue for six (6) months after the effective
date to sell Contract Products then in its inventory (and related containers and
packages in connection therewith) that contain the Trademark at the time of
termination, provided, however, that in no event shall the Trademark be affixed
on such inventory, containers or packages after the effective date of
termination.

                                      -31-

<PAGE>

8. Ownership of Trademark. The Licensee and all parties to this Agreement
acknowledge Licensor's exclusive right, title and interest in and to the
Trademark and any registration that may issue thereon, and will not
intentionally at any time do or cause to be done any act or thing contesting or
in any way impairing or tending to impair part of such right, title and
interest. In connection with the use of the Trademark, neither Licensee nor any
other party hereto shall in any manner represent that he or it has any ownership
in the Trademark or registrations thereof, and all parties acknowledge that use
of the Trademark shall inure to the benefit of the Licensor. On termination of
this Agreement in any manner provided herein, except as otherwise set forth in
Section 6 above, the Licensee will cease and desist from all use of the
Trademark in any way and will deliver up to the Licensor, or its duly authorized
representatives, all material and papers upon which the Trademark appears, and
furthermore, Licensee will not at any time adopt or use without the Licensor's
prior written consent, any word or mark which is likely to be similar to or
confusing with the Trademark.

9. Notices. Any notices required or permitted to be given under this Agreement
shall be deemed sufficiently given if mailed by registered mail, postage
prepaid, addressed to the party to be notified at its address shown above, or at
such other address as may be furnished in writing to the notifying party.

10. Waiver: Modification. No change or modification of this Agreement shall be
valid or binding on the parties hereto, nor shall any waiver of any term or
condition be deemed a waiver of any such term or condition in the future, unless
such change or modification or waiver shall be in writing and signed by the
parties hereto.

11. Severability. In the event any provision or portion of this Agreement shall
be declared invalid by any court of competent jurisdiction, said declaration
shall have no effect upon the remaining provisions of this Agreement, all of
which shall remain in full force and effect and shall constitute the complete
understanding of the parties.

12. Limitation of Liability. In no event shall either party be liable to the
other party under this Agreement for any consequential, incidental, punitive or
other indirect damages except as set forth in Section 10 of the Supply
Agreement.

13. Conflicts. In the event of a conflict between the terms of this Agreement
and the Supply Agreement, the terms of the Supply Agreement shall govern.

14. Applicable Law. The validity and effect of this Agreement shall be governed
by and construed and enforced in accordance with the laws of the State of
Delaware.

NxStage Medical, Inc.

By: /s/ Jeffrey H. Burbank
    ------------------------------

Name:  Jeffrey H. Burbank
       ---------------------------

Title: President & CEO
       ---------------------------

Membrana GmbH

By: /s/ Ulf Seidel                           /s/ Stefan Breiter
    ------------------------------           ------------------------------

Name:  Dr. Ulf Seidel                        Dr. Stefan Breiter

Title: VP Sales and Marketing                Scientific Marketing Manager
       Medical Separations                   Medical Separations

                                      -32-
<PAGE>

APPENDIX 1.: Typeset of Licensed Trademark

The licensed Trademark "PUREMA" must appear as shown below and appear in the
typical PUREMA-red. The logo must not appear in running texts. In running text,
the Trademark is written in upper case in the same font as the text.

PUREMA(R)

colour:

CMYK:    100m 56y 18k

Pantone: 1945

HKS:     17

RAL:     3027

rgb:     175r 17g 54b

                                      -33-

<PAGE>

                                    EXHIBIT A

                          SAMPLE PROMOTIONAL MATERIALS

                                      -34-<PAGE>

          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.

                                                                   Exhibit 10.28

                NxSTAGE/MEDISYSTEMS DISPOSABLES SUPPLY AGREEMENT

     This agreement ("Agreement"), dated as of January 1, 2007 (the "Effective
Date"), is between NxStage Medical, Inc., a Delaware corporation with offices at
439 S. Union Street, 5th Floor, Lawrence, MA 01843 together with its affiliates,
successors and assigns ("NxStage"), and Medisystems Corporation, a Washington
corporation with offices at 701 Pike Street, 16th Floor, Seattle, WA 98101
together with its affiliates, successors and assigns ("MDS").

     In consideration of the mutual promises made herein and other good and
valuable consideration, the receipt of which is hereby acknowledged, the parties
hereto agree as follows:

                                 1.0 BACKGROUND

     1.1 NxStage is in the business of designing, creating Intellectual Property
(as defined in Section 7.3), specifying, out-sourcing, manufacturing,
assembling, distributing, selling and competing with products that perform
extracorporeal blood treatments for patients having chronic or acute renal
insufficiency and/or fluid overload, such treatments incorporating a membrane
blood filter, dialytic or replacement fluids that are approximately isotonic and
a durable electro-mechanical hardware (the "Products"). Such Products include
extracorporeal sets having a substantially plastic blood pathway attachable to
but removable from such durable electro-mechanical hardware ("Sets"). By way of
examples only, blood tubing sets for Fresenius 2008, 3008 and K@Home hardware
are Sets. Sets that also comprise one or more of the following are referred to
herein as "Main Sets":

     a.   Fluid pathways for such isotonic dialytic or replacement fluid
          attached to but removable from such durable electro-mechanical
          hardware (by way of examples only, CAR-160 blood tubing/dialysate sets
          and Gambro Prismaflex sets are Main Sets) and/or,

     b.   FDA-compliant indications for use of such blood and/or isotonic fluid
          pathway(s) for extended use over multiple patient treatments wherein
          such pathway(s) are not removed from such electro-mechanical device
          during such extended use (by way of example only, an Aksys blood
          tubing set is a Main Set) and/or

     c.   FDA-compliant indications for use with batched isotonic fluid sources
          such as bagged dialysate or prepared batches (by way of example only,
          an Aksys blood tubing set/dialysate set and a Gambro Prismaflex set
          are Main Sets).

     1.2 MDS is in the business of designing, creating Intellectual Property,
specifying, out-sourcing, manufacturing, assembling, distributing, importing,
selling and competing with products for: extracorporeal blood management for
patients having chronic or acute renal insufficiency, all of which are Sets;
peritoneal fluid management; extracorporeal pheresis or apheresis for
therapeutic removal or collection of plasma and/or cellular components; IV
therapy; vascular access; port access; topical and device disinfection;
hemostasis; medical access safety; medical connectors; external securement
devices; and any component or assembly of a Set (a "Component" or if controlled
by MDS specifications and/or MDS Intellectual Property, an "MDS Component") as
well as contract assembling and/or manufacturing Sets or Components to

<PAGE>

specifications of OEM purchasers. These products consist of disposable and/or
extended use tube sets, Sets, Main Sets, needle sets, substantially empty bags,
disinfection devices, hemostasis devices, medical kits, connector devices;
securement devices and MDS Components thereof. MDS currently manufactures
certain Products to NxStage Specifications, as defined in Section 2.2 (the
"NxStage Products") for NxStage [**].

     1.3 NxStage designs, manufactures, assembles, licenses, out-sources,
purchases, sells and/or sets Specifications, as defined in Section 2.2, for
certain Main Sets labeled for use with NxStage durable electro-mechanical
hardware (the "NxStage Main Sets"). Components thereof comprise sterile and
unsterile filters ("Filters"), unsterile assemblies ("Assemblies") and unsterile
parts ("Parts") specified by NxStage (together the "Componentry" or if such
Componentry is controlled by NxStage specifications and/or NxStage Intellectual
Property, the "NxStage Componentry"). Some Codes (as defined in Section 2.1) of
NxStage Componentry NxStage currently manufactures itself or purchases from
third party vendors and supplies to MDS without charge, as further detailed in
Section 6.2, for MDS' assembly together with other third party-supplied NxStage
Componentry, MDS-manufactured Componentry and third party sterilization, all
under NxStage Specifications into Codes of NxStage Main Sets on an
order-by-order basis. NxStage and MDS wish to have a substantial portion of
NxStage's total requirements for all NxStage Main Sets in the Territory (as
defined in Section 3.1) supplied by MDS to NxStage or its licensees, designees,
contractees, distributors, customers, agents, etc. during the Term (as defined
in Section 12.1) of this Agreement.

     1.4 This Agreement relates only to orders issued by NxStage and accepted by
MDS during the Term of this Agreement. Each three (3) consecutive calendar month
period commencing on January 1 constitutes a "Contract Quarter" and each four
(4) consecutive Contract Quarters constitute a "Contract Year".

                          2.0 CODES AND SPECIFICATIONS

     2.1 The individual codes of NxStage Products, including NxStage Main Sets
and Componentry that NxStage intends to purchase initially under this Agreement
from MDS are listed in Exhibit A, as such exhibit may be amended from time to
time pursuant to Section 5 hereof throughout the Term of this Agreement
(together, the "Codes").

     2.2 Each Code of NxStage Products, including each sterile Code of NxStage
Main Sets and unsterile Code of Componentry is controlled by NxStage
specifications as completely documented in NxStage's product data management
software ("PDM" - currently the Agile software application) and the QC Standards
(the "Specifications"). A partial summary of such Specifications is listed in
Exhibit B, as such Specifications with relevant revision control numbers may be
modified pursuant to Section 5.0 (with relevant revision control numbers
indicated for each such modification). Each NxStage Product shall include
Labeling, instructions-for-use, trade names and/or trademarks of NxStage (the
"Labeling") as set forth in such Specifications. In order for NxStage and MDS to
meet their respective obligations under this Agreement, MDS and its affiliated
manufacturer(s) will have access to all NxStage Specifications directly related
to the Codes as documented in NxStage's PDM. NxStage hereby grants MDS a
nonexclusive license to copy and internally use the PDM for the sole purpose of

<PAGE>

complying with its obligations under this Agreement.

     2.3 Within fifteen (15) days of the Effective Date of this Agreement, MDS
shall provide to NxStage certain MDS specifications that are MDS' Confidential
Information (as defined in Section 16.1) regarding the Codes in order for
NxStage to fully define and control NxStage's Specifications for MDS' assembly,
packaging and sterilization of the Codes and for any MDS Component NxStage
specifies as NxStage Componentry (as controlled herein and by Section 5.4)
including: MDS' top level Bill of Materials for each Code; Master Part
Specifications for NxStage Componentry sourced from third party vendors of MDS;
top level Master Part Specifications for MDS-manufactured Components; and
Inspection SOPs and validations for the Codes and NxStage Componentry whether an
MDS Component or third party vendor-sourced Component. NxStage shall review such
MDS Component and/or third party vendor-sourced specifications and accept or
reject them as NxStage Componentry and Specifications or, according to Section
5.4 propose alternate Specifications.

                           3.0 PURCHASES AND DELIVERY

     3.1 MDS shall have the Codes produced from one or more manufacturing sites,
at least one of which shall be affiliated with MDS, [**] and MDS shall sell such
Codes to NxStage, and NxStage shall purchase and take delivery of the Codes
within the United States for sale, inventory or use by NxStage within North
America (the "Territory"). NxStage may also ship such purchased Codes for,
inventory, sale and use anywhere outside of the Territory.

     3.2 During the Term of this Agreement, any NxStage requirements for sales,
use and inventory within the Territory of Main Sets, including any such
requirements of any NxStage licensee, contractee, agent, or distributor within
the Territory are defined as NxStage's "Net Requirements". Except for the first
(1st) Contract Quarter during the Term of this Agreement, NxStage hereby agrees
to purchase from MDS a quantity and value of NxStage Main Sets equal to no less
than ninety percent (90%) of NxStage's Net Requirements during each Contract
Quarter during the Term of this Agreement, each such ninety percent (90%) of
NxStage's Contract Quarter Net Requirements throughout the Term being NxStage's
"Main Set Commitment".

     3.3 During the Term of this Agreement, MDS hereby agrees not to
manufacture, distribute, inventory or sell to or for any party other than
NxStage:

     a) outside the Territory, any NxStage Main Set;

     b) inside the Territory, any Main Set;

     c) worldwide, any NxStage Componentry which is not also an MDS Component;

     d) worldwide, any NxStage Componentry which includes any NxStage patentable
     intellectual property, even if such NxStage Componentry is also an MDS
     Component; and

     e) inside the Territory, any MDS Component sold for use with any Main Set
     or NxStage Main Set provided such MDS Component is also NxStage Componentry
     by action of NxStage's right-of-first-refusal provision in Section 7.1.

     Notwithstanding the foregoing, MDS may manufacture, distribute, inventory,
use or sell

<PAGE>

or continue to make, distribute, use or sell to or for any party:

     i)   worldwide, any product or Set that is not a Main Set;

     ii)  worldwide, any Main Set MDS currently manufactures as of the Effective
          Date other than a NxStage Main Set;

     iii) outside the Territory any Main Set that is not a NxStage Main Set;

     iv)  inside the Territory, any MDS Component not covered by Section 3.3e)
          and

     v)   outside the Territory, any MDS Component whether or not it is also
          NxStage Componentry, except as limited by 3.3d) above.

     3.4 On the 8th day of each month within the Term (said 8th or the closest
following business day being the "Order Date") NxStage shall submit by email to
MDS firm written purchase orders obligating NxStage to purchase and take
delivery of a quantity and value of NxStage Main Sets during a [**] day period
commencing no earlier than [**] days from such Order Date and no later than [**]
days from such Order Date ("a Monthly Period") consistent both with NxStage's
Main Set Commitment and with Section 3.7 for such Monthly Period, as well as
orders for any other Code, each purchase order comprising no more than [**] CIF
Location (as hereinafter defined) (together, a "Delivery Order"). Each Delivery
Order will contain an express reference to this Agreement and will state: (i)
the requested quantity, value and Code(s) of Main Sets and/or Componentry to be
produced under such Delivery Order; (ii) the desired [**] day delivery period(s)
within such Monthly Period (a "Delivery Period") and (iii) CIF Location(s) and
shipment instructions for such Delivery Order. In the event of a discrepancy
between a Delivery Order and this Agreement, the terms of this Agreement shall
take precedence. MDS shall deliver the ordered quantity of Codes within the
stated Delivery Period of each Delivery Order. Absent unusual and necessary
situations to the contrary which MDS shall not unreasonably object to, NxStage
shall place [**] Delivery Order per CIF Location, and the totality of Delivery
Orders for any Monthly Period shall be shipped in approximately equally-spaced
container shipments from MDS to NxStage's Delivery Locations over the Monthly
Period. Such Delivery Periods shall also be scheduled such that all such
Delivery Orders can be delivered through the month, up to the last day of the
Monthly Period but no later.

     MDS shall accept all Delivery Orders made by NxStage for NxStage Main Sets
that are consistent with the requirements of this Agreement, and will provide
written acknowledgement of such acceptance to NxStage within [**] business days
of MDS' receipt of such Delivery Order. If MDS fails to respond to NxStage
within said [**] business days, such Delivery Order shall be deemed accepted by
MDS as issued by NxStage. The Codes produced according to each Delivery Order
shall be controlled by the Specifications then in effect at the time such
Delivery Order was accepted.

<PAGE>

          Notwithstanding the above, should NxStage, pursuant to Section 5,
change the Specifications of a Code or establish a new Code then NxStage shall,
no sooner than the next Order Date, place an initial Delivery Order for such
modified or new Code specifying a Delivery Period no less than [**] and no more
than [**] from the Order Date after such new or modified Specification has been
validated and approved by MDS and NxStage, as controlled by Section 5, unless
the parties mutually agree in writing on an order-by-order basis to a shorter
Delivery Period.

     3.5 NxStage shall, in good faith, provide prompt written notice to MDS if
NxStage determines it failed or will fail to place Delivery Orders to MDS in
accordance with Section 3 necessary to meet NxStage's Main Set Commitment for
any Contract Quarter throughout the Term. MDS may audit NxStage's compliance
with the Main Set Commitment using a national accounting firm not affiliated
with any party hereto. Any such audit shall be done with appropriate protection
of both parties' Confidential Information (as defined in Section 16.0). If MDS
elects to audit NxStage's Main Set Commitment compliance, NxStage shall
cooperate with the designated auditor to assist in such audit. In the event that
any such audit reveals NxStage's compliance with the Main Set Commitment, the
cost of such audit shall be born solely by MDS, otherwise such cost shall be
borne solely by NxStage. If, during any Contract Quarter throughout the Term
NxStage fails to place Delivery Orders in accordance with Section 3 sufficient
to meet the Main Set Commitment, NxStage shall in good faith provide prompt
written notice to MDS of the failure of such Delivery Orders to meet the Main
Set Commitment or if NxStage is found by MDS not to comply with the Main Set
Commitment, for example, by audit or by NxStage notice, NxStage shall, within
[**] of each such event, pay to MDS liquidated damages equal to the value of
such Contract Quarter's Main Set Commitment minus the value of all Delivery
Orders placed during such Contract Quarter, such net value multiplied by [**]
percent ([**]%) (a "Shortfall Payment").

     3.6 Within [**] days of the Effective Date of this Agreement and on the 8th
day of each calendar month thereafter, NxStage shall provide to MDS a good faith
rolling forecast of its anticipated Delivery Orders ("Forecasted Delivery
Orders") to be placed by the Order Dates for each subsequent [**] calendar
months (the "Delivery Order Forecast"). Each such Delivery Order Forecast shall
comprise Forecasted Delivery Orders each in a quantity and value of Main Sets
that shall be equal to or exceed the Main Set Commitment. By the Order Date of
each calendar month during the Term, NxStage shall also submit to MDS, with
appropriate protection of its Confidential Information, NxStage's actual
disbursements from its inventory and prior month's ending inventory for each
NxStage Main Set Code for the previous calendar month and MDS shall disclose to
NxStage by such Order Date MDS' prior month's ending NxStage Componentry
inventory.

     3.7 The first [**] months of Forecasted Delivery Orders of each Delivery
Order Forecast shall constitute a maximum quantity of Codes during each of such
[**] months above which MDS will not be required to accept relevant Delivery
Orders as described below in this Section (the "Support Level"). Notwithstanding
the above, MDS shall use reasonable commercial efforts to accept NxStage
Delivery Orders for NxStage Main Sets in excess of such Support Level to the
degree said Delivery Order Forecast was insufficient due to no fault of NxStage.
NxStage shall be able to manufacture for itself, or obtain from third parties,
any Delivery Orders not accepted by MDS, and such Delivery Orders will be
credited on a unit basis toward the relevant Main Set Commitment, provided that
NxStage supplies MDS with copies of

<PAGE>

such Delivery Orders and the invoices related thereto or sufficient
documentation evidencing NxStage's manufacture of such Codes.

          The first [**] months of Forecasted Delivery Orders of each rolling
Delivery Order Forecast shall constitute a firm commitment by MDS for acceptance
of and on-time delivery of the relevant Delivery Orders placed by the relevant
Order Date of the specified forecasted total quantity of Codes related to such
first [**] months' Forecasted Delivery Orders according to the following
formulae: a) the [**] month's Forecasted Delivery Order of each Delivery Order
Forecast shall constitute a firm commitment by NxStage to place a Delivery Order
by the next Order Date that is equal in value to such [**] month's Forecasted
Delivery Order, and b) the [**] months' Forecasted Delivery Orders shall
constitute a firm commitment by NxStage to place Delivery Orders by the Order
Date in the next [**] following calendar months that (i) for Main Set volumes
between Tiers 1 and 3 of Exhibit C, are not greater than [**] per cent ([**]%)
nor less than [**] per cent ([**]%) of the value of such [**] months' Forecasted
Delivery Orders, (ii) for Main Set volumes between Tiers 4 and 7 of Exhibit C,
are not greater than [**] percent ([**]%) nor less than [**] percent ([**]%) of
the value of such [**] months' Forecasted Delivery Orders, and (iii) for Main
Set volumes between Tiers 8 through 11, are not greater than [**] percent
([**]%) nor less than [**] percent ([**]%) of the value of such [**] months'
Forecasted Delivery Orders. Except as otherwise provided hereunder, the
remainder of the good faith Delivery Order Forecast shall be non-binding on
NxStage.

     3.8 For each rolling Delivery Order Forecast, the [**] such month's
Forecasted Delivery Order referenced in Section 3.7 shall constitute
authorization by NxStage for MDS to order relevant quantities of any NxStage
Componentry and necessary materials from the relevant third party vendors as
well as to begin production of any relevant MDS-manufactured Componentry
sufficient to produce the related Delivery Order. And each such [**] month's
Forecasted Delivery Order shall authorize MDS to order from NxStage relevant
quantities of any NxStage-supplied NxStage Componentry necessary to produce the
related Delivery Order and such NxStage Componentry order shall obligate NxStage
to deliver all such ordered NxStage-supplied NxStage Componentry to MDS at MDS'
designated location within [**] days of MDS' placement of such order (a "NxStage
Componentry Delivery Order"). In addition, such [**] month's Forecasted Delivery
Order constitutes a firm commitment by NxStage to reimburse MDS for all such
materials, Componentry or completed Codes if NxStage does not place Delivery
Orders sufficient to consume such materials, Componentry or completed Codes
within the rolling [**]-month period following the forecast delivery date;
provided that the amount of such reimbursement shall be credited against any
Shortfall Payments made by NxStage during such rolling [**]-month period.

     3.9 If MDS experiences an interruption or significant slow-down in its
assembly of Main Sets then, to the degree such interruption or slow-down is the
fault of NxStage, examples of which are listed in Exhibit E, MDS shall charge
and NxStage shall pay to MDS an hourly production interruption charge
("Interruption Charge") according to the rates listed in Exhibit C, as such
Exhibit may change from time to time according to Section 5. MDS will apply
reasonable commercial efforts to avoid and/or minimize Interruption Charges. MDS
may not claim any Interruption Charge for any interruption or significant
slow-down in assembly caused by any (i) MDS-manufactured Component, except for
reasons listed specifically in the MDS-supplied Componentry section of Exhibit E
or (ii) failure by NxStage to timely fulfill NxStage Componentry Delivery Orders
due to an event of force majeure on NxStage as set forth in

<PAGE>

Section 3.16. To the degree any such interruption or significant slow-down is
the fault of NxStage and delays the delivery of any Delivery Order beyond the
relevant Delivery Period, such Delivery Period shall be extended by such delay.
Any disputes between MDS and NxStage related to Interruption Charges shall be
adjudicated by the Quality Dispute Resolution process defined in Section 9.8.

     3.10 If, due to an NNC (as defined in Section 5.4) NxStage changes a
Specification or NxStage makes a temporary deviation order to a Specification of
an in-process Delivery Order (a "Temporary Deviation") and such change or
Temporary Deviation results in an interruption or significant slow-down of
supply of MDS-manufactured Components or third party-sourced Componentry or
assembly of NxStage Main Sets, then MDS may invoice NxStage an Interruption
Charge according to the rates listed in Exhibit C, as such Exhibit may change
from time to time according to Section 5, provided MDS will apply reasonable
commercial efforts to avoid and/or minimize such Interruption Charges.

     3.11 Within [**] of the Effective Date of this Agreement, the parties will
cooperate with each other to complete a plan to address contingency supply
arrangements which are to be made to assure continuity of supply of NxStage Main
Sets from MDS to NxStage through unforeseeable events (the "Disaster Recovery
Plan"). The Disaster Recovery Plan shall be reviewed by both parties at least
[**] times per Contract Year, at which time both parties may agree to commission
a redundant operation such as an additional manufacturing and/or assembly
facility to MDM, second sub-contractor, etc. as part of the Disaster Recovery
Plan to better assure NxStage Main Set supply. NxStage acknowledges that MDS'
costs of NxStage Main Sets from such redundant operation(s) may differ from
those costs from MDM, and as such MDS is entitled to adjust pricing for NxStage
Main Sets to recover increased costs to the degree they are produced by the
redundant operation(s). Such MDS Code price adjustment shall be controlled by
the terms of Section 5.4.

     3.12 In the event NxStage and MDS do not renew this Agreement in accordance
with Section 12.2 hereof, then for the final four (4) consecutive Contract
Quarters of the Term the Main Set Commitment shall be reduced for such Contract
Quarters to: [**] percent ([**]%), [**] percent ([**]%), [**] percent ([**]%)
and [**] percent ([**]%) of NxStage's Net Requirements during such Contract
Quarter.

     3.13 Except as set forth in Section 3.9, 3.10 and 3.15, if MDS is unable to
deliver Codes during the Delivery Period applicable to any Delivery Order, or
MDS replaces Codes pursuant to Sections 9.3, 9.4, 11.2 or 15.6, MDS will deliver
or replace the Codes as soon as possible, on an expedited basis at MDS' expense.
With respect to Codes which MDS is unable to deliver against a Delivery Order
within [**] days of the Delivery Period (a "Late Shipment") and where NxStage
manufactured for itself or purchased NxStage Main Set Codes from other suppliers
to meet its immediate needs ("Fill-In Codes"), such Fill-In Codes orders will be
credited on a unit basis toward the relevant Main Set Commitment, provided that
NxStage supplies MDS with copies of such orders and the invoices related thereto
or sufficient documentation evidencing NxStage's manufacture of the Fill-In
Codes. In addition, to the extent that the cost of Fill-In Codes manufactured by
NxStage or purchased from unaffiliated third party suppliers collectively
exceeds the then applicable prices of the Codes that were filled-in,

<PAGE>

MDS will credit NxStage for such excess cost toward the price of the relevant
Delivery Order, provided however, that such credit shall not exceed [**]%) of
the then applicable prices of the Codes which were filled-in. NxStage's purchase
of Fill-In Codes does not relieve NxStage of its obligations to take delivery
and pay for Late Shipments, to the degree such delivery is no later than within
sixty (60) days of the Delivery Period.

     3.14 Notwithstanding Sections 3.2 and 3.4, NxStage may be relieved of its
Main Set Commitment, in whole or in part, at NxStage's option, should MDS be in
material breach of this Agreement, if such breach is uncured (i) within one
hundred twenty (120) days after MDS receives written notice from NxStage
adequately documenting such breach, or (ii) should MDS be in material breach of
this Agreement for more than 120 days, whether or not consecutive, during any 12
month rolling period within the term of this Agreement. Specifically to delivery
obligations not subject to force majeure, if MDS does not completely deliver any
Delivery Order within sixty (60) days of the Delivery Period, NxStage shall be
relieved of its Main Set Commitment.

     3.15 MDS assumes no liability and shall not be liable to NxStage for any
failure to fill or delay in filling Delivery Orders to NxStage where such
failure or delay is caused by events beyond the reasonable control of MDS,
including, without limitation, strikes, lockouts, floods, fires or accidents. In
the event of any such failure or delay, MDS shall use reasonable commercial
efforts to fulfill NxStage's Delivery Orders in a timely fashion. MDS shall
notify NxStage promptly if it anticipates any potential delay in the filling of
any of NxStage's Delivery Orders caused by any of the above. Notwithstanding the
above, if any Set manufacturer competitive to MDS such as Fresenius, Gambro,
Nipro and/or JMS suffers a force majeure event or FDA action that substantially
reduces the ability of any such manufacturer to supply the U.S. market with any
Set, MDS may allocate increases above NxStage's Support Level as defined in
section 3.7, in its manufacturing and/or assembly output to NxStage and to
others at MDS' sole discretion or as ordered by the FDA.

     3.16 NxStage assumes no liability and shall not be liable to MDS for any
failure to fill or delay in filling any NxStage Componentry Delivery Order to
MDS or failure to place or delay in placing any NxStage Delivery Order where
such failure or delay is caused by events beyond the reasonable control of
NxStage, including, without limitation, strikes, lockouts, floods, fires,
accidents. In the event of any such failure or delay, NxStage shall use
reasonable commercial efforts to fulfill Componentry Delivery Order requirements
to MDS in a timely fashion and to place NxStage's Delivery Orders in a timely
fashion. NxStage shall notify MDS promptly if it anticipates any potential delay
in Delivery Order placement or the filling of any of MDS' requirements caused by
any of the above.

                              4.0 SHIPMENT OF CODES

     4.1 MDS will ship the Codes C.I.F. to [**] as more completely listed in
Exhibit C and as such C.I.F. location(s) may be changed from time to time.
NxStage agrees to pay [**] for the freight charge from [**]. NxStage will ship
the NxStage Componentry C.I.F. to [**], or other U.S. address as MDS may
instruct from time to time during the Term. Title to and risk of loss for the
Codes shall pass from MDS to NxStage upon delivery of the Codes by MDS to [**]
or such other C.I.F. Location agreed to by both parties.

<PAGE>

     4.2 MDS and NxStage, as the case may be, shall prepare and send by
facsimile or email transmission to the other a packing list for each shipment of
the Codes or NxStage Componentry. Each party shall notify the other party if any
shipment will not be delivered during the Delivery Period applicable to a
Delivery Order.

     4.3 Each party will notify the other party by facsimile or email
transmission of any receiving discrepancy (over, short or damaged), within [**]
days of receipt of such discrepant delivery. Each party hereby agrees to hold
the entire shipment (or such relevant part) intact pending timely resolution by
the other party. Each such party hereby agrees, within [**] business days from
receipt of such notice, to arrange for verification of and provide a schedule of
cure of such receiving discrepancy. In the event of a receiving discrepancy, for
the purpose of Section 6.1, each Party's invoice will be deemed to have been
dated on the date the other party effects such cure.

             5.0 PRICING, SPECIFICATION CHANGES AND PRODUCT CHANGES

     5.1 As of the Effective Date and throughout the Term of this Agreement MDS
agrees to sell to NxStage the initial NxStage Main Set Code at the prices for
all volume tiers (the "Tiers") listed in Exhibit C (the "Baseline Prices").
NxStage represents that such initial NxStage Main Set Code is defined by the
NxStage Specifications as summarized in Exhibit B and completely documented in
NxStage's PDM, and are the complete Specifications for such initial NxStage Main
Set Code as of the Effective Date. Baseline Prices and Specifications for such
NxStage Main Set Code shall only be adjusted pursuant to the procedures set
forth in Section 5.

          Within fifteen (15) days of the Effective Date, MDS shall disclose to
NxStage in a format similar to and to the degree of detail defined in Exhibit L,
the unit dollar ($) standard costs of direct material, direct labor, and fixed
and variable overhead for MDS at MDM which together with MDS' unit dollar ($)
gross profit total the Baseline Prices for all Tiers of the initial NxStage Main
Set Code at MDM (the initial "Open Book Accounting"). MDS represents that such
initial Open Book Accounting shall be made according to standard accounting
practices for the Tier One mid-point volume of NxStage Main Set production MDS
produces at MDM as of the Effective Date (the "Tier One Open Book Accounting")
and such standard costs have been determined based on actual production results
during 2006. Notwithstanding the above, the cost of any MDS Component accepted
by NxStage as a NxStage Componentry has been incorporated into such Open Book
Accounting totally under the direct material category at such MDS Component's
arm's length negotiated price between MDS and NxStage, and such cost has not
been further broken down into the direct material, direct labor, fixed and
variable overhead cost or profit elements required by MDS to manufacture or
supply such MDS Component as a NxStage Componentry. By way of example only, as
of the Effective Date such MDS Components accepted by NxStage as NxStage
Componentry comprises extruded tubing, [**] and molding services for NxStage
spike assembly parts. The Baseline Prices at all Tiers have been negotiated at
arm's length between NxStage and MDS, however MDS represents that such Tier One
Open Book Accounting reflects the same labor and overhead absorption rates as
MDS uses for its own Set production at MDM. MDS represents that the Baseline
Prices for Tiers Two through Eleven in Exhibit C are MDS' good faith estimates
of such Open Book Accounting

<PAGE>

resulting from timing and volumes of Tiers Two through Eleven and experience
gained as well as from certain predicted targeted cost reduction projects
("Reserved Cost Downs") listed in Exhibit M. NxStage accepts that in order for
MDS to agree to the Baseline Prices in Tiers Two through Eleven that MDS
requires the relevant Reserved Cost Downs accepted by NxStage and instituted no
later than for the Tier disclosed in Exhibit M. MDS must inform NxStage in
advance of investing capital to implement a Reserved Cost Down, and NxStage must
approve such investment in order to assure that future NNCs will not obsolete
such investment prior to full depreciation. Reserved Cost Downs shall be part of
Open Book Accounting.

          MDS agrees throughout the Term of this Agreement to continue to offer
to NxStage the MDS Component known as [**] specifically bearing MDS code and
specification revision [**], for incorporation as NxStage Componentry into any
NxStage Main Set or NxStage Componentry used in any NxStage Main Set at the
relevant prices for such [**] listed for all Tiers in Exhibit C. No subsequent
or different MDS specification of any [**] introduced by MDS shall relieve MDS
of the above obligation; provided however, except to the degree provisions of
Section 7.1 are applicable, MDS is under no obligation to offer NxStage any [**]
with such subsequent or different MDS specification.

          Initial prices for Codes other than NxStage Main Sets and Componentry
thereof ("Non-Main Set Prices") are listed in Exhibit C, and such prices may be
modified only by mutual agreement of the parties during the initial [**]
Contract Years. Non-Main Set Prices are not guaranteed beyond the initial [**]
Contract Years and are not subject to open book accounting.

     5.2 If any Assembly ordered by NxStage from MDS for further assembly by
NxStage has Specifications identical to those of an Assembly of a currently
produced NxStage Main Set Code, whether or not such Assembly comprises
Intellectual Property controlled by MDS or its affiliates, then MDS agrees that
pricing to NxStage throughout the Term for such Assembly shall exclude any
lot-specific charges and comprise only the relevant Open Book Accounting
elements consistent with Section 5.1 attributable to such Assembly, if disclosed
in Exhibit L to such detail, of such related Assembly provided that such
Assembly is ordered and produced with the same production run as such related
NxStage Main Set. If there is any dispute, such pricing shall be subject to
audit by a third party reasonably acceptable to and with Confidential
Information requirements of MDS, whose decision in conformance with this
Agreement shall be accepted by both parties. Notwithstanding the above, MDS will
have no obligation to accept any Assembly or Componentry order from NxStage that
is inconsistent with NxStage's Main Set Commitment; provided that for orders
placed within the last [**] years of this Agreement, MDS will have no obligation
to accept any Assembly or Componentry comprising more than [**] percent ([**]%)
of NxStage's Net Requirements, unless NxStage provides reasonably sufficient
documentation with such orders demonstrating that such quantities are reasonably
forecasted by NxStage as needed to fulfill NxStage Main Set orders outside of
the Territory.

     5.3 No less than [**] each Contract Year on each anniversary of the
Effective Date, but no more frequently than every [**] months of such Contract
Year, MDS or NxStage may obtain price adjustments to the Baseline Prices or
Accepted Revised Prices (as hereinafter defined), as calculated using Exhibit D
in the event of changes above a thresh-hold rate (as set forth in Exhibit D) in
MDS' relevant cost elements listed in Exhibit D, such changes determined

<PAGE>

from the later of i) the Effective Date of this Agreement; ii) the last previous
periodic price adjustment or iii) the last previous approved NxStage Notice of
Change (as hereinafter defined) which resulted in an Accepted Revised Price as
defined in Section 5.4.

     5.4 NxStage or MDS may at any time propose to add to, reduce or modify the
existing Specifications of any Code including any related QC Standards (as
defined in Section 9.1), or either party may propose to replace or add a Code at
any time. Any proposals by MDS to add to, reduce or modify the existing
Specification of any Code, including any related QC Standards, or to replace or
add a Code, must expressly indicate whether such proposal involves the
incorporation of any MDS Component and stipulate whether or not such MDS
Component comprises an MDS-controlled patent or pending patent at the time of
such MDS proposal. Such MDS proposal in MDS' sole judgment, subject only to
Section 7.1, shall describe whether and on what price, temporal and quality
terms NxStage would have access to such MDS Component for use in NxStage
Products during the Term and/or following the termination of this Agreement. The
price of any proposed MDS Component shall be incorporated into such proposal and
any subsequent Open Book Accounting totally under the direct material category
at such MDS Component's arm's length negotiated price between MDS and NxStage
and such cost shall not be further broken down into the direct material, direct
labor, fixed and variable overhead cost or profit elements required by MDS to
manufacture or supply such MDS Component. If such proposal is acceptable to
NxStage in NxStage's sole judgment or NxStage makes its own proposal, NxStage
shall fully define such proposal to MDS in writing, signed by a Vice President,
Senior Vice President or the President of NxStage, using a form substantially
equivalent to Exhibit F ("NxStage Notice of Change" or "NNC") including the
relevant NxStage PDM changes necessary to effect such NNC. Such NNC shall
include a proposed implementation schedule which both parties acknowledge may be
a major determinant of pricing of such NNC. Within [**] days after receipt of
the NNC, MDS shall be obligated to respond to NxStage with MDS' assessment of
the NNC in technical terms and an estimated implementation schedule including
MDS' new proposed price(s) for such NNC for such Code, including without
limitation, any fees relating to the incorporation of MDS Intellectual Property
into such Code, and any other costs estimated to be reasonably incurred by MDS
made necessary by such NNC, which include, but are not limited to, costs of
obsolete inventory, vendor cancellation charges (including restocking fees) and
the impact of production costs on the price of NxStage Codes not affected by
such NNC. MDS shall use commercially reasonable efforts to mitigate all such
other costs.

          In the case of a NxStage Main Set Code NNC, such new proposed price(s)
shall include a revised Open Book Accounting ("Revised Open Book Accounting")
comprising the new direct material, direct labor and variable overhead unit
standard costs of MDS at MDM, or the manufacturing site at which applicable
Codes are then manufactured, which together with MDS' unit fixed overhead and
gross profit, shall total the proposed price for such Main Set Code NNC (A
"Proposed Revised Price") at all Tiers. In addition, MDS shall propose the costs
of any required tooling, factory modifications or any other relevant
non-recurring engineering costs, such as the above-listed costs ("NR Costs")
necessary to effect such NNC.

<PAGE>

          If an NNC, Proposed Revised Price or relevant proposed price and
related costs for a Code are acceptable to NxStage, in its sole judgment, such
proposed price or Proposed Revised Price(s) shall become an accepted revised
price ("Accepted Revised Price") that will be entered in Exhibit C. Such
acceptance may only be given to MDS in a written document signed by a Vice
President, Senior Vice President or the President of NxStage. Receipt of this
written acceptance shall cause the Specifications of such Code to be changed in
compliance with the MDS and NxStage Specification documentation change control
processes and no change shall be effected without adherence to such change
control processes.

          Notwithstanding the above, no NNC shall result in a new or modified
Specification until both NxStage and MDS have approved an implementation
schedule to implement such NNC, which approval each party shall not unreasonably
withhold or delay. A Temporary Deviation Notice for any Code is agreed by both
parties to be a Specification change and both parties shall follow all
procedures regarding Specification changes, though to the degree possible, on an
expedited basis. The parties agree that applicable FDA design control and
quality system regulations shall be interpreted as allowing no Temporary
Deviation to remain in effect for more than [**] without agreement of MDS or
without effecting the formulaic sharing of the Net Cost Change (as herein
defined) according to this Section 5.4. Notwithstanding this, the parties
further agree that if a Temporary Deviation is implemented for no more than [**]
then the cost effect of such Temporary Deviation will be determined by MDS in
arrears and in good faith to include only costs MDS incurred without application
of the formulaic sharing of any Net Cost Change according to this Section 5.4
and such costs shall be promptly paid to MDS by NxStage. If any Temporary
Deviation or any immediately subsequent Temporary Deviation substantially
equivalent to such prior Temporary Deviation, are in effect for no more than
such [**], then the lifting of such Temporary Deviation(s) shall also result in
no application of the formulaic sharing of any Net Cost Change according to this
Section 5.4 at the return to the Specification in effect prior to such Temporary
Deviation(s).

          Notwithstanding which party proposed such Main Set Code NNC, NxStage
and MDS agree to share the Net Cost Change resulting directly from such NxStage
Main Set Code NNC. Such Net Cost Change is defined as the net change in MDS and
MDM's unit dollar ($) standard costs directly and solely related to the proposed
Main Set Code NNC, of direct labor, direct material (including any MDS Component
at its arms' length negotiated price), variable overhead and, only to the degree
relevant at other Tiers, fixed overhead. NxStage shall accept as an Accepted
Revised Price any Proposed Revised Price for a relevant NxStage Main Set Code
NNC according to the following formulae and representing:

          a) a price reduction equal to [**] percent ([**]%) of any estimated
Net Cost Change savings, and

          b) a price increase equal to [**]%) of any estimated Net Cost Change
increase divided by (one minus gross profit margin percentage) where the gross
profit margin percentage equals the gross profit margin percentage at the
relevant volume tier from the initial version of Exhibit L, the Open Book
Accounting.

<PAGE>

          Notwithstanding the above, no NNC shall result in any Net Cost Change
reduction or its formulaic sharing to the degree any relevant cost reduction
element is a Reserved Cost Down listed in Exhibit M at the relevant Tier. To the
degree NR Costs are charged to and paid by NxStage and not added to MDS'
depreciation, no NR Cost shall be included in the Net Cost Change sharing
calculation. To the degree tooling, fixtures, etc. of any NNC are to be
depreciated by MDS, then such depreciation shall be included in Variable
Overhead.

          By way of examples only, a number of scenarios involving Revised
Baseline Prices, Reserved Cost Down, NR Costs, Accepted Revised Prices, arms'
length negotiated MDS Components, Net Cost Change sharing and the operation of
this Section 5 are listed in Exhibit O.

          MDS shall maintain the Revised Open Book Accounting records for all
Codes of NxStage Main Sets through the Term of the Agreement and for two (2)
years thereafter which reconcile the impact of all NNCs and their relevant
Accepted Revised Price changes back to the initial Baseline Pricing for each
Tier.

     5.5 NxStage at its discretion and expense and with reasonable notice may
have the Open Book Accounting audited no more than once per year by a third
party reasonably acceptable to and with Confidential Information requirements to
MDS. Such third party's decision shall be accepted by both parties. MDS has an
obligation during the Term of this Agreement to maintain detailed histories of
cost and pricing changes of the Main Sets during the Term of this Agreement and
for two (2) years thereafter to facilitate such audit.

     5.6 Notwithstanding the above, if any government authority makes any demand
on MDS for payment of any monies related to the manufacture, transport,
inventory, sale or use of the Codes, including Componentry thereof, other than
taxes relating to the income of MDS, such payment not reasonably foreseen by
MDS, NxStage shall reimburse MDS for such payments. MDS shall use reasonable
commercial efforts to determine the legality of such government demand and to
legally avoid such payments wherever possible.

                                   6.0 PAYMENT

     6.1 The terms of payment for the Codes invoiced by MDS to NxStage under
this Agreement shall be [**] percent ([**]%), [**] days, net [**] days from
MDS's invoice date, as determined by the wire transfer date of NxStage's
relevant wired payments. MDS may invoice for Codes on the date they arrive at
the CIF Location. Any undisputed outstanding MDS invoice amounts, including
service charges, not received by MDS within [**] days from such invoice date
shall be subject to a service charge until paid, in an amount equal to the
lesser of [**] percent ([**]%) per month or the maximum rate allowed by law. In
addition, if full payment for each MDS undisputed invoice is not received by MDS
within [**] days from MDS' invoice date, MDS may restrict weekly sales and
shipments to NxStage to a dollar amount equal to the payments received from
NxStage in the previous week. Such restriction will not put MDS in breach of
this Agreement. If full payment is not received by MDS within [**] days from
MDS'

<PAGE>

undisputed invoice date, NxStage shall be considered to be in material breach of
this Agreement and subject to Section 13.1. Any NxStage dispute of an MDS
invoice shall be made in good faith and be related only to an error in such
invoice and NxStage must notify MDS within [**] days of NxStage's receipt
thereof, and the parties shall work together in good faith to resolve any
disputes. If the parties are unable to resolve the invoice dispute within [**],
the parties shall each appoint an expert consultant, with expertise in the
relevant area, to resolve the dispute. The two appointed expert consultants
shall endeavor in good faith to resolve the dispute within a subsequent [**]. If
the consultants can not reach agreement within this period of time, the parties
agree to submit the dispute to binding arbitration in accordance with JAMS
rules.

     6.2 The terms of payment for any NxStage Componentry Delivery Order
supplied by NxStage and purchased by MDS shall be [**] percent ([**]%), [**]
days, net [**] days from NxStage's invoice date, as determined by the credit
date or wire transfer date of MDS' wired payments. Notwithstanding the above,
NxStage shall not charge for any [**], but shall supply such Filter, FMP and
Tray without charge to MDS. Such [**] shall remain the property of NxStage and
shall be preserved and safe-guarded by MDS with at least the same degree of care
that MDS preserves and safeguards its own property. MDS agrees that it shall be
responsible for any damage to such NxStage-supplied NxStage Componentry while in
its possession other than any damage incurred by following the Specifications,
and that it shall return within [**] of any NxStage written request any such
NxStage Componentry to NxStage not required by MDS to fulfill any accepted
Delivery Order. MDS shall reimburse NxStage for all damage to Filters, FMP
Assemblies or Trays while such NxStage-supplied NxStage Componentry is in MDS'
physical possession and up to and including until the related NxStage Main Sets
are delivered to NxStage. Notwithstanding the above, MDS shall not be
responsible for damage to Filters, FMP Assemblies or Trays up to [**] percent
([**]%) of the value of such NxStage-supplied NxStage Componentry, as measured
on an aggregate dollar basis by month. Further notwithstanding the above and
except for gross negligence, willful misconduct by MDS or failure by MDS to
exercise the same degree of care in manufacturing NxStage Codes that it takes
with MDS' own sets, MDS shall not be liable for loss of or damage to such
NxStage-supplied NxStage Componentry by reason of any recall, scrap or failure
to release NxStage Main Sets until and unless NxStage adopts Specifications
allowing for [**] sterilizations of NxStage Main Sets and a labeled "shelf life"
of at least [**] years from sterilization date. NxStage may invoice MDS for any
NxStage Componentry Delivery Order after arrival of the relevant goods at the
C.I.F. Location. Any undisputed NxStage Componentry Delivery Order invoice
amounts, including service charges, not received by NxStage within [**] days
from such invoice date shall be subject to a service charge until paid, in an
amount equal to the lesser of [**] percent ([**]%) per month or the maximum rate
allowed by law. If full payment of any undisputed invoice is not received by
NxStage within one hundred (120) days of NxStage's invoice date, MDS shall be
considered to be in material breach of this Agreement and subject to Section
13.1. Disputed invoices shall be governed by the same terms as Section 6.1.

     6.3 All NxStage or MDS payments are to be remitted by wire transfer to the
specific bank or financial institution designated respectively by MDS and
NxStage to receive such payments.

                  7. MDS COMPONENTRY AND INTELLECTUAL PROPERTY

<PAGE>

     7.1 During the Term of this Agreement, NxStage shall have a
right-of-first-refusal to pre-empt any MDS offer to sell to any third party
within the Territory any MDS Component for incorporation into any Main Set
provided, however, that such MDS Component is covered by at least one
MDS-controlled patent in the United States or patent-pending and further
provided that NxStage's use of such MDS Component is limited to incorporation
into NxStage Main Sets or NxStage Componentry manufactured by MDS for NxStage
during the term of this Agreement. MDS shall make no such third party offer
without advising such third party in writing of NxStage's right-of-first-refusal
and MDS shall provide NxStage with a true copy of all terms of such third party
offer within [**] business days of such third party offer. Such NxStage
right-of-first-refusal shall exist for [**] days from the issue date of any such
MDS offer and NxStage's pre-emption shall be limited to NxStage's acceptance of
the specific terms of such offer in its entirety.

          If NxStage does not exercise such right-of-first-refusal during such
[**] days, then MDS may sell such MDS Component to such third party including
for use in any Main Set. Any change in any term of any such MDS offer creates a
new NxStage right-of-first-refusal for a further [**] days.

          If NxStage does exercise such right, Section 5.4 shall control
NxStage's acceptance of any such MDS Component as NxStage Componentry and
incorporation into a NxStage Main Set. For any such MDS Component so
incorporated by NxStage into a NxStage Main Set, any subsequent sale or license
by MDS to any third party for such MDS Component shall obligate MDS to require
that such third party may not incorporate such MDS Component into any Main Set
or NxStage Main Set for sale or use inside the Territory during the Term of this
Agreement.

     7.2 As of the date hereof, the designs of all Codes are the Intellectual
Property of NxStage, except for the MDS Components which have been accepted by
NxStage as NxStage Componentry as set forth in Exhibit A, the design(s) of
which are the Intellectual Property of MDS.

     7.3 "Intellectual Property" means all inventions, processes, discoveries,
other novel or valuable information, patents, trademarks, copyrights, and any
applications or registration thereof and trade secrets whether owned, used or
licensed by or to either party or employees and/or agents (the "NxStage
Intellectual Property" or the "MDS Intellectual Property" as the case may be).
Inventor-ship of Intellectual Property will be determined according to U.S
patent law.

     7.4 Nothing in this Agreement affects the ownership by any party or their
employees and/or agents of any Intellectual Property owned or in the possession
of such party or their employees and/or agents as of the Effective Date of this
Agreement. During the Term of this Agreement, all Intellectual Property
developed by either party or their employees and/or agents that is independent
of the specific operation of this Agreement shall remain the property of such
developing party or their employees and/or agents.

     7.5 Intellectual Property, whether or not patentable, that is developed in
performance
<PAGE>

of this Agreement but is made solely by employees and/or agents of NxStage and
does not comprise any MDS Confidential Information or MDS Intellectual Property
disclosed by MDS, will be assigned by such employees and/or agents to NxStage
and shall be defined for purposes of this Agreement as NxStage Intellectual
Property. By way of example only and without limiting the foregoing, any NxStage
customer's or vendor's identity is the Intellectual Property of NxStage even if
such customer or vendor was developed solely in performance of this Agreement;
provided that any such NxStage customer's or vendor's identity shall cease to be
NxStage Intellectual Property if the same ceases to be NxStage Confidential
Information, as defined in the Confidentiality Agreement as set forth in Exhibit
J.

     7.6 Intellectual Property, whether or not patentable, that is developed in
performance of this Agreement but is made solely by employees and/or agents of
MDS and does not comprise any NxStage Confidential Information or NxStage
Intellectual Property disclosed by NxStage, will be assigned by such employees
and/or agents to DSU Medical Corporation, an affiliate of MDS, and shall be
defined for purposes of this Agreement as MDS Intellectual Property. By way of
example only and without limiting the foregoing, any MDS customer's or vendor's
identity is the Intellectual Property of MDS even if such customer or vendor was
developed solely in performance of this Agreement; provided that any such MDS
customer's or vendor's identity shall cease to be MDS Intellectual Property if
the same ceases to be MDS Confidential Information, as defined in the
Confidentiality Agreement as set forth in Exhibit J.

     7.7 Intellectual Property, whether or not patentable, that is developed in
performance of this Agreement and is made jointly by an employee(s) and/or
agent(s) of both parties, or is made by one party's employee(s) and/or agent(s)
and comprises the Confidential Information or Intellectual Property of the other
party will be assigned by such employee(s) and/or agent(s) according to the
employment agreement of such employee(s) and/or agent(s) and the parties shall
assign to the other party, rights in such Intellectual Property so that such
Intellectual Property is jointly owned (the "Joint Inventions"). Such Joint
Inventions shall remain as trade secrets unless a decision to apply for a patent
is made with the express written joint consent of MDS and NxStage, which shall
share equally the reasonable costs of prosecuting, maintaining and defending
such Joint Inventions. Such Joint Inventions may not be used by MDS or NxStage,
or licensed or disclosed by MDS or NxStage to any third party without the
express written joint consent of MDS and NxStage during the term of any patent
or in accordance with the terms of the confidentiality agreement of Exhibit J
herein regarding any trade secret.

                    8.0 REGULATORY RESPONSIBILITY; LABELING;
                                   TRADE NAMES

     8.1 NxStage shall be responsible, at its expense, for complying with all
applicable regulatory requirements of the U.S. Food and Drug Administration
("FDA") relating to the sale or use of the Codes including, but not limited to,
obtaining authorization under Section 510(k) of the United States Federal Food,
Drug and Cosmetic Acts, as amended (the "Acts"). MDS shall be responsible, at
its expense, for complying with applicable regulatory requirements of the FDA
relating to its supply of the Codes, including, but not limited to, maintaining
proper registration with the FDA of all MDS manufacturing facilities used in the
supply of the Codes. NxStage shall immediately notify MDS of any change in the
regulatory status of any Code. MDS shall

<PAGE>

immediately notify NxStage of any change in regulatory status of, or regulatory
inspection involving, any of the MDS manufacturing facilities involved in the
supply of any Code, and shall use its best efforts to promptly address any
deficiencies or other concerns raised in connection with such a regulatory
inspection.

          NxStage shall be responsible also for compliance with the Code of
Federal Regulations, Title 21, Part 803, Medical Device Reporting ("MDR"), with
regard to any end-user complaint received by either party involving the Codes
supplied to NxStage by MDS. NxStage shall have sole and exclusive responsibility
for handling complaints relating to the Codes, for making MDR determinations
with respect to such complaints and for filing MDR reports relating to the
Codes. NxStage, within [**] of its determination that a NxStage complaint may by
related to an area(s) of MDS responsibility, shall provide to MDS documentation
sufficient for MDS to investigate such complaint according to the Act. MDS has
no responsibilities with respect to complaint handling other than for such
documented complaints provided to MDS. For all such written complaints MDS shall
(i) provide assistance to NxStage in connection with compliant investigations,
(ii) notify NxStage in writing within [**] of any complaints or MDRs received by
MDS relating to the Codes, (iii) notify NxStage in writing within [**] of any
FDA 483 or warning letter reports involving the same MDS manufacturing
facilities or processes used by MDS in supplying the Codes hereunder, (iv) and
notify NxStage within [**] of MDS' issuance of any Corrective and Preventive
Action ("CAPA") to correct a defect in a component or process used in a NxStage
Product. Without limiting the foregoing, MDS may not file MDR reports relating
to the Codes unless required by any applicable Federal Regulation, and unless
NxStage is notified thereof prior to such report being filed. If requested to
provide assistance in a complaint investigation, MDS shall diligently evaluate
all information supplied by NxStage or already in the possession of MDS relating
to such complaint within [**] of receipt of information and/or samples from
NxStage and shall promptly submit to NxStage a completed complaint communication
form which form shall be substantially in the form of Exhibit H.

          MDS shall have no obligation or liability to ensure that, and makes no
representation or warranty that, any Code complies with any applicable product
standards, regulations or laws, but agrees to give to NxStage any reasonable
assistance requested in order to demonstrate that the Codes supplied by MDS do
so comply.

     8.2 NxStage shall, at its expense, provide the Labeling including all
camera-ready artwork necessary for MDS to produce the Codes.

     8.3 Each use on the Codes of any NxStage trademarks, trade names or logos
shall inure to the benefit of NxStage. Should any such use vest in MDS any
rights in any NxStage trade mark, trade name or logo, MDS shall transfer such
rights to NxStage or its designee upon request of NxStage. Each use on the Codes
of any MDS trademarks, trade names or logos shall inure to the benefit of MDS.
Should any such use vest in NxStage any rights in any MDS trade mark, trade name
or logo, NxStage shall transfer such rights to MDS or its designee upon request
of MDS.

     8.4 Except as provided in this Agreement, MDS and NxStage will not use any
trade mark, trade name or logo of the other party, or any trademark, trade name
or logo confusingly

<PAGE>

similar therewith, during or after the Term of this Agreement.

     8.5 NxStage shall maintain the device master record ("DMR") and final
release device history record ("Final DHR") for all NxStage Codes and shall be
responsible for final release of NxStage Codes under 21 CFR Part 820 for
commercial sale to third parties or clinical use.

                               9.0 QUALITY CONTROL

     9. 1 The term "Lot" shall mean all Codes bearing the same sterilization or
production lot number. Each Lot of Codes made by MDS and sold by MDS to NxStage
shall be subject to in-coming and in-process quality control inspections and
release testing by MDS in accordance with NxStage's quality standards for
NxStage Codes sufficient to meet the relevant Specifications as determined by
NxStage-specified AQLs subject to NxStage-determined inspection levels and
sampling plans, as such terms are defined by [**] as listed for the Codes in
Exhibit G (the "QC Standards").

          MDS shall inform NxStage of any Specifications that MDS reasonably
believes will not be controlled by the QC Standards. Not withstanding this, the
Specifications are owned and controlled by NxStage. NxStage shall have the
option to amend the Specifications. MDS shall also apply reasonable commercial
efforts to manage MDM manufacturing operations to effect continuous product
quality improvements for the NxStage Products.

     9.2 MDS warrants that each Lot of the Codes at the time title to such Lot
is transferred to NxStage will comply with the Specifications as controlled by
the requirements of the QC Standards then in effect at the time the Delivery
Order relevant to such Lot was accepted by MDS.

     9.3 At its discretion, NxStage may inspect or audit the Lots of Codes or
MDS-manufactured Componentry sold to NxStage for adherence to the Specifications
as controlled by the requirements of the QC Standards then in effect at the time
the Delivery Order relevant to such Lot was accepted by MDS. NxStage shall
conduct such inspection or audit within [**] of receipt by it of each shipment.
If as a result of this timely inspection any Lot fails to conform to the
Specifications as controlled by the requirements of the QC Standards, NxStage,
in addition to any other remedies it may have hereunder, may, at its option,
obtain from MDS credit for or refund for all Codes or such Componentry in such
Lot, plus the cost of all NxStage-supplied Componentry not paid for by MDS
incorporated in such Lot, except as otherwise provided in Section 6.2, or, if
mutually agreed by NxStage and MDS, NxStage shall receive replacement of all
Codes or such Componentry in such Lot, and be reimbursed for the cost of all
NxStage-supplied Componetry not paid for by MDS incorporated in such Lot, except
as otherwise provided in Section 6.2. However, if MDS requests, NxStage will
allow MDS to have an independent laboratory, to be previously consented to by
NxStage, which consent shall not be unreasonably withheld, audit any suspect
Lot. The decision of such independent laboratory as to whether such Lot complies
with the Specifications as controlled by the requirements of the QC Standards
will be final.

<PAGE>

     9.4 If any customer of NxStage rejects or returns Codes to NxStage as a
result of any alleged failure of any Lot of Codes to meet the Specifications as
controlled by the requirements of the QC Standards then in effect at the time of
MDS' acceptance of the Delivery Order related to such Lot, MDS shall be notified
in writing by NxStage within [**] of each such rejection or return comprising a
good faith description of MDS' alleged relationship to such alleged failure. If
NxStage in good faith alleges such failure such rejected or returned Lot units
may be returned to MDS, at MDS' expense, provided that such Lot units are
returned within [**] days of MDS' receipt from NxStage of the customer complaint
regarding such Lot. However, if MDS requests, NxStage will allow MDS to have an
independent laboratory, to be previously consented to by NxStage, which consent
shall not be unreasonably withheld, audit compliance with such Specifications of
any such rejected or returned Lot units as well as sufficient other units from
the same Lot in order to create a valid sample size for such audit of such Lot
to such Specifications as controlled by the requirements of such QC Standards.
The decision of such independent laboratory as to whether such Lots comply with
the Specifications as controlled by the requirements of the QC Standards will be
final, but only if a sufficient sample size has been so tested. At MDS' expense,
NxStage shall receive, at NxStage's option, a credit or refund for such Lot
units found to not meet such Specifications, plus the cost of all
NxStage-supplied Componentry not paid for by MDS incorporated in such Lot,
except as otherwise provided in Section 6.2, or by mutual agreement of NxStage
and MDS, NxStage shall receive replacements for such Lot units, and be
reimbursed for the cost of all NxStage-supplied Componentry not paid for by MDS
incorporated in such Lot, except as otherwise provided in Section 6.2. If such
returned Lots or Lot Units are not found to not meet Specifications as
controlled by the QC Standards as of the time title transfers to NxStage, of
which the AQLs, sampling plans and inspection levels are an integral part,
NxStage shall reimburse MDS for MDS' costs of such returns. NxStage shall use
all commercially reasonable efforts to mitigate damages to MDS resulting from
the requirement of this Article 9 and Article 11 to pay for the cost of all
NxStage-supplied NxStage Componentry not paid for by MDS and incorporated into
Lots not meeting Specifications.

     9.5 NxStage warrants that the Componentry specified by NxStage is deemed to
meet the NxStage Specifications of such Componentry, as controlled by the
requirements of the QC Standards then in effect at the time such Componentry
passes inspection at MDS according to such QC Standards. In addition, at its
option, NxStage may ask MDS to perform tests on each Lot of such Componentry
before it is released for subsequent operations by MDS, to assure compliance
with NxStage Specifications, as controlled by the requirements of the QC
Standards then in effect. If NxStage elects the latter, NxStage shall pay to MDS
such testing costs as are listed on Exhibit C.

          If MDS reasonably determines by subsequent operations that, despite
MDS' testing to the QC Standards and/or NxStage's warranty to the QC Standards,
any Componentry or Code does not meet NxStage's Specifications or QC Standards
on either a Unit basis or Lot basis, MDS shall attempt to secure authorization
from NxStage to proceed with heightened testing of such Componentry or Code Lot
Units or Lots, scrapping of such Componentry or Code Lot Units or Lots, rework
or other disposition of such Componentry or Code Lot Units or Lots believed to
be so affected. MDS shall not be liable for errors or omissions in this regard
as long

<PAGE>

as such errors or omissions are not negligent and MDS exhibits reasonable good
faith in its efforts. MDS shall invoice NxStage for all of MDS' costs involved
in such heightened testing, rework, scrap, downtime and other items previously
authorized by NxStage, and NxStage shall pay such invoices within [**] days of
receipt.

     9.6 NxStage warrants that the design, bill-of-materials, schematics,
assembly drawings, test specifications, sampling protocols and procedures called
for in the Specifications and QC Standards are such that the Codes when
manufactured by MDS to the Specifications as controlled by the requirements of
the QC Standards then in effect at the time of MDS' acceptance of the Delivery
Order related to such Lot, and subsequently stored and handled by NxStage in
accordance with the Labeling meet the Specifications as controlled by the
requirements of the QC Standards through the expiration date for the Codes
indicated in the Labeling.

     9.7 NxStage shall have the right to hire an independent third party quality
auditor, not affiliated with NxStage or MDS, and reasonably acceptable to MDS,
who shall, at reasonable times, upon prior notice in writing and with
representatives of MDS present, visit MDS' facilities or MDS vendor facilities
periodically to review the production and quality control standards, systems,
procedures and records of MDS or its vendors directly related to the Codes for
the purpose of reporting to NxStage any deficiencies in MDS' or vendor
facilities' quality control systems in meeting the relevant sections of [**] or
the QC Standards. NxStage personnel shall have the right with sufficient notice
to MDS to review the documentation and records of production, quality control
standards, systems, procedures and production areas of MDS directly related to
the Codes.

          MDS shall have the right to hire an independent third party quality
auditor, not affiliated with NxStage or MDS, and reasonably acceptable to
NxStage, who shall, at reasonable times, upon prior notice in writing and with
representatives of NxStage present, visit NxStage facilities or NxStage vendor
facilities periodically to review the production and quality control standards,
systems, procedures and records of NxStage or its vendors directly related to
the Componentry supplied to MDS by NxStage for the purpose of reporting to MDS
any deficiencies in such facilities' quality control systems.

     9.8 MDS and NxStage agree to work in good faith to resolve all disputes
relating to the QC Standards under this Agreement, including without limitation,
disputes relating to product warranty, incoming component quality, continuous
product quality improvement, and interruption charges relating to alleged
quality issues. Without limiting the foregoing, if these or other quality
related issues can not be solved in the routine course of business, the parties
agree to meet within [**] upon the request of either party to resolve any such
quality disputes. If the parties are unable to reach agreement in good faith
within this [**] period, the parties shall each appoint an expert quality
consultant, recognized in the medical device field, to resolve the dispute. The
two appointed expert consultants shall endeavor in good faith to resolve the
dispute within [**]. If the consultants can not reach agreement within this
period of time, the parties agree to submit the dispute to binding arbitration
in accordance with JAMS rules.

                               10.0 VENDOR CONTROL

<PAGE>

     10.1 MDS, as assembler of the Codes, shall be responsible for control over
each vendor (including MDS and NxStage) of Componentry listed on the Bill of
Materials of each Code according to the following terms:

          a. to the degree a vendor discloses to and agrees with MDS to terms
and conditions of trade, such disclosure and agreement to be fully disclosed by
MDS to NxStage and agreed to by NxStage and MDS, MDS shall be responsible for
reasonable commercial control of such vendor to such agreed-upon-terms and
conditions and

          b. to the degree a vendor discloses to and agrees with MDS regarding
specifications as controlled by the requirements of vendor's quality control
standards, such disclosure and agreement to be fully disclosed by MDS to NxStage
and agreed to by NxStage and MDS, MDS shall be responsible for reasonable
commercial control of such vendor's componentry supply or sterilization services
to such vendor agreed-upon specifications as controlled by such quality
standards.

     10.2 NxStage shall have the right to supercede any vendor's agreed-upon
componentry specification and/or vendor's relevant quality standard with a more
restrictive Componentry Specification as controlled by a relevant QC Standard
for MDS, as assembler, to use in the assembly of a relevant Code. However, if
such more stringent Specification and/or relevant QC Standard is not agreed to
by such vendor, then MDS cannot be held responsible for control of such vendor
to such more stringent Specification or QC Standard. Further, to the degree such
Specification is more stringent than the relevant vendor's agreed upon
Specification then MDS' responsibility as assembler of the Codes is only to
diligently apply the relevant QC Standard to accept or reject such Componentry
for further assembly into Codes. In such an event, the parties agree that the
relevant Code Specifications MDS is required to meet shall be no more
restrictive than the relevant agreed-upon specifications of such relevant
vendor's componentry used in such Code, except that MDS shall diligently apply
the relevant QC Standard whether to accept each lot of vendor's componentry as
Componentry in the further assembly of any Code.

                      11.0 WARRANTIES AND INDEMNIFICATIONS

     11.1 Subject to Sections 9.6 and 10.2, MDS warrants for the labeled
shelf-life of all Codes that Codes sold to NxStage under this Agreement will be
in compliance with the Specifications as controlled by the requirements of the
QC Standards then in effect at the time of MDS' acceptance of the Delivery Order
related to such Lot. EXCEPT AS SET FORTH IN THE PRECEDING SENTENCE, MDS MAKES NO
REPRESENTATION OR WARRANTY WHATSOEVER, WRITTEN OR ORAL, EXPRESS OR IMPLIED, AS
TO ANY OF THE CODES, OR THEIR MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE, AND MDS HEREBY EXPRESSLY DISCLAIMS ANY SUCH REPRESENTATION AND
WARRANTY. ALL OF THE WARRANTIES SET FORTH IN THIS SECTION 11.1 ARE VOID AND OF
NO EFFECT IF THE CODES ARE NOT STORED IN ACCORDANCE WITH THE DIRECTIONS ON THE
LABELING ON OR ACCOMPANYING THE CODE.

     11.2 NxSTAGE ACKNOWLEDGES AND AGREES THAT, EXCEPT AS TO ACTIONS OF MDS
WHICH CONSTITUTE NEGLIGENT, RECKLESS, OR WILLFUL MISCONDUCT, AND EXCEPT AS IS
OTHERWISE PROVIDED FOR IN ARTICLES 3, 8, 9

<PAGE>

AND 15 HEREOF, MDS' SOLE RESPONSIBILITY TO NxSTAGE IN THE CASE OF BREACH OF THE
FOREGOING WARRANTY SHALL BE FOR MDS, BY MUTUAL AGREEMENT OF NxSTAGE AND MDS, TO
REPAIR OR REPLACE THE CODES WITH RESPECT TO WHICH SUCH WARRANTY IS BREACHED, AND
TO REIMBURSE NxSTAGE FOR THE COST OF ALL NxSTAGE-SUPPLIED COMPONENTRY NOT PAID
FOR BY MDS INCORPORATED INTO SUCH CODES, EXCEPT AS OTHERWISE PROVIDED IN SECTION
6.2, OR, AT NxSTAGE'S ELECTION, TO RETURN ALL PAYMENTS MADE BY NxSTAGE TO MDS
WITH RESPECT TO SUCH CODES AND TO REIMBURSE NxSTAGE FOR THE COST OF ALL
NxSTAGE-SUPPLIED COMPONENTRY NOT PAID FOR BY MDS INCORPORATED INTO SUCH CODES,
EXCEPT AS OTHERWISE PROVIDED IN SECTION 6.2, OR TO CREDIT NxSTAGE IN THE AMOUNT
OF ALL PAYMENTS MADE BY NxSTAGE TO MDS WITH RESPECT TO SUCH CODES PLUS THE COST
OF ALL NxSTAGE-SUPPLIED COMPONENTRY NOT PAID FOR BY MDS INCORPORATED INTO SUCH
CODES, EXCEPT AS OTHERWISE PROVIDED IN SECTION 6.2. IN NO EVENT SHALL EITHER
PARTY BE LIABLE FOR THE OTHER'S LOSS OF PROFITS, LOSS OF USE, OR INCIDENTAL,
CONSEQUENTIAL, SPECIAL OR OTHER INDIRECT DAMAGES OF ANY KIND.

     11.3 MDS shall indemnify and hold NxStage and its affiliates harmless from
and against all claims, liability, damage, loss, cost or expense of NxStage,
including its reasonable attorneys' fees arising out of, or in connection with,
or as a result of the (i) failure of any of the Codes to meet the warranty set
forth in Section 11.1 or (ii) infringement of a third party intellectual
property right if the infringement did not result from the compliance by MDS
with the Specifications supplied by NxStage. In order to discharge its
obligations under this Section 11, MDS shall obtain and keep in force during the
Term of this Agreement, product liability insurance with a limit of liability of
not less than $10,000,000. The insurance policy evidencing such insurance shall
be endorsed to name NxStage as an additional insured and provide for written
notification to NxStage by the insurer not less than thirty (30) days prior to
cancellation, expiration, or modification of such insurance. A certificate of
insurance from MDS' insurer evidencing compliance with the insurance
requirements of this Section 11.3 shall be given to NxStage by MDS within thirty
(30) days after the signing of this Agreement.

     11.4 Each party shall communicate to the other party all charges of alleged
infringement of any third party intellectual property right within a reasonable
time after their receipt. The parties will cooperate fully with each other in
defending or otherwise resolving any charges of infringement.

     11.5 NxStage shall indemnify and hold MDS and its affiliates harmless from
any and all claims, liability, damages, loss, cost, or expense (including
reasonable attorneys' fees) arising out of, based on, or caused by: (a) any
product claims, representations, descriptions or other statements, whether oral
or written, made or alleged to be made by NxStage or its representatives in any
Labeling, instructions, advertising, publicity, promotion or sale of any of the
Codes; (b) any product claim arising out of, based on, or caused by negligent
handling of the Codes by NxStage or its agents; (c) any product claim arising
out of defects in the design of the Codes or Specifications or QC Standards
supplied by NxStage or failure of the Codes to be fit for any particular
purpose, or (d) a third party infringement claim not covered under Section 11.3,
except

<PAGE>

in each instance to the extent such claim, liability, loss, cost or expense
arises out of, or is based on, or caused by (i) the negligence or willful
misconduct of MDS, or (ii) any failure of the Codes to meet applicable
Specifications or other breach by MDS of the terms of this Agreement. In order
to discharge its obligations under this Section 11, NxStage shall obtain and
keep in force during the Term of this Agreement, product liability insurance
with a limit of liability of not less than $10,000,000 within one (1) year from
the Effective Date and no less than $5,000,000 during the first Contract Year.
The insurance policy evidencing such insurance shall be endorsed to name MDS as
an additional insured and provide for written notification to MDS by the insurer
not less than thirty (30) days prior to cancellation, expiration, or
modification of such insurance. A certificate of insurance from NxStage's
insurer evidencing compliance with the insurance requirements of this Section
11.5 shall be given to MDS by NxStage within thirty (30) days after the signing
of this Agreement.

                             12.0 TERM OF AGREEMENT

     12.1 The term ("Term") of this Agreement shall be for the period beginning
on the Effective Date of this Agreement and ending after seven (7) consecutive
Contract Years.

     12.2 Unless the parties mutually agree in writing twelve (12) months prior
to the end of the Term, this Agreement shall not be renewed, in which case
section 3.12 shall take effect.

                                13.0 TERMINATION

     13.1 Subject to Section 3.14 hereof, either party may terminate this
Agreement for any material breach by the other party, by giving one-hundred
twenty (120) day written notice to the other party, if such breach shall, as of
the expiration of said one-hundred twenty (120) day period remain uncured.

     13.2 Either party may terminate this Agreement effective immediately upon
the giving of notice, if the other party shall file a petition in bankruptcy, or
shall be adjudicated a bankrupt, or shall take advantage of the insolvency laws
of any state, or shall make an assignment for the benefit of creditors, shall be
voluntarily or involuntarily dissolved, or shall have a receiver, trustee or
other court officer appointed for its property.

     13.3 All Confidential Information and Intellectual Property not
specifically allowed by written contract to be used post-Agreement shall be
returned to the relevant party upon termination of this Agreement for any
reason. Any post-Agreement use by either party of such other party's
Confidential Information disclosed during the Agreement shall be governed by the
terms of the Confidentiality Agreement detailed in Exhibit J.

                           14.0 EFFECT OF TERMINATION

     14.1 No termination of this Agreement, other than by reason of breach of
this Agreement by NxStage, will relieve MDS from its obligation to deliver all
Codes ordered by any Delivery Order of NxStage received by MDS prior to the date
of written notice of such termination, nor will any termination, other than by
reason of breach of this Agreement by MDS

<PAGE>

or except as otherwise provided herein, relieve NxStage from accepting and
paying for all Codes ordered by NxStage under any Delivery Order issued by
NxStage prior to the date of such written notice of termination or relieve
NxStage of its obligation pursuant to Sections 3.2 and 3.4. Upon any termination
of this Agreement, MDS shall promptly return to NxStage all NxStage-supplied
Componentry not paid for by MDS or tooling, fixtures, etc. for NxStage
production not paid for by MDS.

                               15.0 PRODUCT RECALL

     15.1 NxStage shall have the sole right and responsibility for electing to
recall worldwide any Lot or partial Lot of the Codes distributed or caused to be
distributed by NxStage. NxStage shall administer such recall. NxStage shall
consult with MDS in good faith regarding any recommendations made by MDS
relating to whether NxStage may institute a recall. Subject to Section 15.4
below, NxStage shall initially bear all out-of-pocket costs and expenses of such
recall, including, without limitation, refunds to customers for recalled Lots,
the cost of notifying customers, and costs associated with the shipment of
recalled Codes from customers to NxStage or MDS. NxStage shall maintain complete
and accurate records, for such periods as may be required by applicable law, of
all the Lots sold by NxStage.

     15.2 In the event of a recall of any Lot or partial Lot of the Codes
distributed or caused to be distributed by NxStage, the parties will cooperate
fully with each other in effecting such a recall, including without limitation
promptly contacting any purchasers and communicating to such purchasers any
information or instructions that NxStage elects to communicate to such
purchasers.

     15.3 In the event of a recall of any Lot or partial Lot of the Codes
distributed or caused to be distributed by NxStage where MDS and NxStage cannot
agree on the responsible party, MDS and NxStage will have an independent
laboratory, previously consented to by NxStage and MDS, which consent shall not
be unreasonably withheld, audit sufficient recalled Lot units to determine if
such Lot is in compliance with the Specifications, including all QC Standards.
If the recalled Lots meet the Specifications, including all QC Standards then in
effect at the time of MDS' acceptance of the Delivery Order related to such Lot
then, subject to Section 15.4 below, NxStage shall bear all costs and expenses
of the recall, including the cost of the audit. If the recalled Lots do not meet
the Specifications, including all QC Standards, subject to Section 15.4 below,
MDS shall bear all costs and expenses of the recall including the cost of the
audit. Notwithstanding the above, if sufficient Lot units are not available to
comprise a statistically significant sample size, yet a statistically
significant increase in reported field failures attributable to the Product over
prior Lots is recorded, the parties agree to use the Quality Dispute Resolution
process as outlined in Section 9.8 to determine responsibility for the recall.
Notwithstanding the outcome of the Quality Dispute Resolution process, MDS and
NxStage shall cooperate on proposed manufacturing, design, or testing to address
the field failures.

     15.4 In the event of a recall of any Lot of Codes or partial Lot of Codes,
MDS or NxStage may, once the recall has been substantially completed, invoke the
Quality Dispute Resolution process as defined in Section 9.8, which outcome
shall determine whether NxStage's initiation of recall was necessary and
reasonable. The Quality Dispute Resolution process may

<PAGE>

result in arbitration which may require that NxStage or MDS bear all costs,
damages and expenses, including reasonable attorney's fees of such recall or may
apportion such costs and expenses between the parties as the arbitrator deems
just. Notwithstanding the above, the obligations of either party to the other
shall be subject to the limitations set forth in the last sentence of 11.2.

     15.5 NxStage shall bear all costs and expenses of a recall to the degree
caused by the negligence of NxStage or its agents or customers, improper or
incorrect Specifications, inadequate QC Standards, defective Componentry
supplied by NxStage or its vendors, or by breach of NxStage's regulatory
responsibility as set forth in Section 8.0. MDS shall bear all costs and
expenses of a recall to the degree caused by the negligence of MDS or its agents
or vendors, or by breach of MDS' regulatory responsibility as set forth in
Section 8.

     15.6 If, and to the extent MDS is required by operation of this Agreement
to bear the costs of a recall, and as a result of such recall NxStage orders and
purchases from another supplier, or manufactures for itself, replacement product
codes for recalled Codes, such replacement code orders shall be credited on a
unit basis toward the applicable Main Set Commitment, provided, however, that
NxStage shall supply MDS with copies of such orders and the invoices related
thereto or appropriate documentation of its manufacturing costs. In addition, to
the extent that the cost of such replacement products purchased from an
unaffiliated third party supplier, or manufactured by NxStage, exceeds the then
applicable prices of the Codes that were replaced, MDS will credit NxStage for
such excess cost, provided however, such credit shall not exceed [**] percent
([**]%) of the then applicable MDS prices of the Codes which were replaced.

                          16.0 CONFIDENTIAL INFORMATION

     16.1 The terms relating to confidential information ("Confidential
Information") mutually agreed to by NxStage, MDS and their respective employees
and agents are contained in Exhibit J.

                              17.0 OTHER PROVISIONS

     17.1 This Agreement contains the entire agreement between the parties
relating to the subject matter herein and all prior proposals, discussions, and
writings by and between the parties and relating to the subject matter herein
are superseded by this Agreement. None of the terms of this Agreement shall be
deemed to be waived by either party or amended unless such a waiver or amendment
is in writing and is signed by the party to be charged with such waiver or
amendment, and such writing recites specifically that it is a waiver of, or
amendment to, the terms of this Agreement.

     17.2 Except for Delivery Orders, forecasts, NNCs and the like, which may be
sent by email, all notices and demands required or permitted to be given or made
pursuant to this Agreement shall be addressed as follows:

     If to NxStage:

<PAGE>

                      President
                      NxStage Medical, Inc.
                      439 S. Union Street, 5th Floor
                      Lawrence, MA 01843
                      jeffb@nxstage.com
                      Fax: 978-687-4805

                      With a copy to NxStage's General Counsel at the same
                      address

     If to MDS:

                      President
                      Medisystems Corporation
                      701 Pike Street, 16th Floor
                      Seattle, WA 98101
                      d.utterberg@medisystems.com
                      Fax: (206) 834-1301

or to such other address as to which either party may properly notify the other.
All notices, requests and other communications hereunder shall be in writing and
shall be deemed to have been duly given at the time of receipt if delivered by
hand, by a nationally recognized overnight delivery service or by facsimile
transmission or three (3) days after being mailed, registered or certified mail,
return receipt requested, with postage prepaid, to the address or facsimile
number (as the case may be) listed for each such party or, if any party shall
have designated a different address or facsimile number by notice to the other
parties given as provided above, then to the last address or facsimile number so
designated.

     17.3 This Agreement shall be binding upon and inure to the benefit of the
parties, their successors and permitted assigns and shall survive a Change of
Control of either party, as defined in Exhibit I. This Agreement shall be
assignable by either party with the written consent of the other; provided,
however, that either party may assign this Agreement to any entity controlled by
or under common control with such party and in such event the assigning party
shall provide the other party with written notice of such assignment. Without
limiting the foregoing, this Agreement and the Main Set Commitment of NxStage
shall be the obligation and responsibility of any third party that acquires,
through sale, license or other transfer, NxStage Intellectual Property
sufficient to make, use or sell any NxStage Main Set (a "NxStage IP Control
Change") and NxStage agrees that as a condition of any such NxStage IP Control
Change such third party shall execute an instrument, in form and substance
reasonably satisfactory for MDS, confirming such obligation and responsibility.
Following such Change of Control and/or NxStage IP Control Change, such Main Set
Commitment shall only apply to NxStage Main Sets incorporating NxStage
Intellectual Property and shall not apply to other Main Sets then made, or
subsequently made, by such successor, assignee or new owner of such sufficient
NxStage Intellectual Property.

     Should any Change of Control of MDS be to a successor, purchaser or under
common control of an entity that manufactures, or sells products and provides
in-center dialysis within the Territory (for example at present, Fresenius
Medical Care North America, Inc.), then if such successor or purchaser fails to
completely deliver any Delivery Order within [**] of the end of

<PAGE>

the relevant Delivery Period, except due to an event of force majeure, then such
successor or purchaser shall pay to NxStage damages equal to [**]% of the then
relevant Baseline Prices or Accepted Revised Prices (whichever the case may be)
times the current Net Requirements times the number of Monthly Periods remaining
in the Term of the Agreement.

     17.4 This Agreement is deemed to have been entered into in the State of
Washington and its interpretation, construction, and the remedies for its
enforcement or breach are to be applied pursuant to and in accordance with the
laws of the State of Washington.

     17.5 In the event that a court of competent jurisdiction holds that
particular provisions or requirements of this Agreement are in violation of any
law, such provisions or requirements shall be enforced and shall remain in full
force and effect to the extent they are not in violation of any such law or are
not otherwise unenforceable, and all other provisions and requirements of this
Agreement shall remain in full force and effect.

<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their authorized representatives as of the date first set forth above.

                                        NxSTAGE MEDICAL, INC.

                                        By: /s/ Jeffrey H. Burbank
                                            ------------------------------------
                                             Jeffrey H. Burbank
                                             President
                                             Jan. 4, 2007

                                        MEDISYSTEMS CORPORATION

                                        By: /s/ David S. Utterberg
                                            ------------------------------------
                                            David S. Utterberg
                                            President
                                            Jan. 3, 2007

<PAGE>

LIST OF EXHIBITS

A Codes
B Specifications and Labeling
C Prices and Interruption Charges
D Price Adjustment Formulae for Supply Cost Changes
E Examples of Causes for Assessment of Interruption Charges
F NxStage Notice of Change
G Intentionally Left Blank
H Intentionally Left Blank
I Definition of Change of Control
J Confidential Information Agreement
K Intentionally Left Blank
L Open Book Accounting and Revised Open Book Accounting
M Reserved Cost Downs
N Complete costed Bill of Materials
O Examples of Revised Baseline Prices, etc.
<PAGE>

                                EXHIBIT A - CODES

<TABLE>
<CAPTION>
                        CODES
PART#   DESCRIPTION   REVISION   MDS IP INCLUDED?
-----   -----------   --------   ----------------
<S>     <C>           <C>        <C>
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]       [**]
[**]    [**]          [**]
[**]    [**]          [**]
[**]    [**]          [**]
</TABLE>

<PAGE>

                                    EXHIBIT B

                           Specifications and Labeling

[**]

<PAGE>

EXHIBIT C - PRICES AND INTERRUPTION CHARGES

     Draft NxStage Quotation based on: __________

     NxStage Requirements Forecast_[**]
                                 [**]
                                 [**]

<TABLE>
<CAPTION>
                                       VOLUME RANGE
                                 -----------------------
    TIER       FORECASTED TIER   MIN.   MID-POINT    MAX   CAR-160   CAR-170
    ----      ----------------   ----   ---------   ----   -------   -------
                   Timing
<S>           <C>                <C>    <C>         <C>    <C>       <C>
TIER ONE         [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER TWO         [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER THREE       [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER FOUR        [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER FIVE        [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER SIX         [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER SEVEN       [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER EIGHT       [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER NINE        [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER TEN         [**]   [**]     [**]      [**]     [**]     [**]      [**]

TIER ELEVEN      [**]   [**]     [**]      [**]     [**]     [**]      [**]
</TABLE>

INTERRUPTON CHARGES PAID BY NXSTAGE TO MDS SHALL BE EQUAL TO:

                 [**]
                 [**]
                 [**]

<PAGE>

                                    EXHIBIT D

         PRICE ADJUSTMENT FORMULAE COVERING CHANGES IN MDS' SUPPLY COSTS

<TABLE>
<CAPTION>
Item                                          Trigger                       Application Factor                Source Document
------------------------------   ---------------------------------   --------------------------------   ---------------------------
<S>                              <C>                                 <C>                                <C>
1. Cost of Purchased Materials   [**]% or more in material           Relevant Cost prior to Trigger     Actual invoices
                                                                     Point + change in cost

2. Cost of Shipping and Import   [**]% or more in shipping costs     Relevant Cost prior to Trigger     Actual invoices
Clearance                        or clearance costs                  Point +/- change in cost

3. Exchange Rates.               [**]% or more in exchange rates     Relevant Costs prior to Trigger    Wall Street Journal or
                                                                     Point +/- change in cost           similar publication

4. Duty and other Governmental   [**]% or more in exchange rates     Duty and  other governmental       Government gazette or other
Import related charges                                               import related charges prior to    official promulgation
                                                                     Trigger Point +/- change in cost
</TABLE>

<PAGE>

                                    EXHIBIT E

            EXAMPLES OF CAUSES FOR ASSESSMENT OF INTERRUPTION CHARGES

[**]
<PAGE>

EXHIBIT F - NXSTAGE NOTICE OF CHANGE

<TABLE>
<S>                      <C>                                    <C>
(NXSTAGE LOGO)           NXSTAGE NOTICE OF CHANGE (NNC)         NNC NUMBER _____

NNC ORIGINATED BY:                                   DATE ORIGINATED:
                   -----------------------------                      ----------
Signature not required

Complete section A and subsequent applicable sections. This form may be expanded
to multiple pages as necessary.

A.   DESCRIPTION OF CHANGE

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

B.   REASON/EXPLANATION \ FOR CHANGE
     [ ] PART OBSOLESCENCE [ ]   IMPROVED COST [ ]   IMPROVED QUALITY

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

C.   AFFECTED ITEMS (ATTACH SCANNED REDLINES)

ITEM NUMBER   DESCRIPTION                               OLD REV.   PROPOSED REV.
-----------   ---------------------------------------   --------   -------------

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________

___________   _______________________________________   ________   _____________
</TABLE>

CONFIDENTIAL

THIS DOCUMENT IS THE PROPERTY OF NXSTAGE MEDICAL, INC. AND MAY           FORM227
NOT BE REPRODUCED WITHOUT THE WRITTEN PERMISSION OF THE           Draft 1, Rev 1
MANAGEMENT OF NXSTAGE MEDICAL, INC.                                  Page 1 of 4

<PAGE>

<TABLE>
<S>                      <C>                                    <C>
(NXSTAGE LOGO)           NXSTAGE NOTICE OF CHANGE (NNC)         NNC NUMBER _____

D.   PROPOSED VALIDATION PLAN

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

E.   PROPOSED IMPLEMENTATION PLAN AND SCHEDULE

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

F.   ESTIMATED COST IMPLICATIONS

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

     ___________________________________________________________________________

G.   NXSTAGE APPROVAL OF THE NNC

     --------------------------------------------
     VP OF MANUFUCTURING OR VP OF DISPOSABLE R&D:               DATE:
     Signature required                                               ----------
</TABLE>

CONFIDENTIAL

THIS DOCUMENT IS THE PROPERTY OF NXSTAGE MEDICAL, INC. AND MAY           FORM227
NOT BE REPRODUCED WITHOUT THE WRITTEN PERMISSION OF THE           Draft 1, Rev 1
MANAGEMENT OF NXSTAGE MEDICAL, INC.                                  Page 2 of 4

<PAGE>

<TABLE>
<S>                      <C>                                    <C>
(NXSTAGE LOGO)           NXSTAGE NOTICE OF CHANGE (NNC)         NNC NUMBER _____

     --------------------------------------------
     DISPOSABLES QA:                                            DATE:
     Signature required                                               ----------

H.   MEDISYSTEMS RESPONSE: Complete section H and applicable sections. This form
     may be expanded to multiple pages as necessary.

     1.   ASSESSMENT OF CHANGE:

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

     2.   PROPOSED IMPLEMENTATION PLAN & SCHEDULE:

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

     3.   COST IMPLICATIONS - ATTACH "OPEN BOOK" DOCUMENTATION

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

     4.   PROPOSED REVISED PRICING:

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

          ______________________________________________________________________

     5.   MEDISYSTEMS APPROVAL OF THE NNC

     --------------------------------------------
     VP OF OPERATIONS:                                          DATE:
     Signature required                                               ----------
</TABLE>

CONFIDENTIAL

THIS DOCUMENT IS THE PROPERTY OF NXSTAGE MEDICAL, INC. AND MAY           FORM227
NOT BE REPRODUCED WITHOUT THE WRITTEN PERMISSION OF THE           Draft 1, Rev 1
MANAGEMENT OF NXSTAGE MEDICAL, INC.                                  Page 3 of 4

<PAGE>

<TABLE>
<S>                      <C>                                    <C>
(NXSTAGE LOGO)           NXSTAGE NOTICE OF CHANGE (NNC)         NNC NUMBER _____

     --------------------------------------------
     DISPOSABLES QA:                                            DATE:
     Signature required                                               ----------
</TABLE>

CONFIDENTIAL

THIS DOCUMENT IS THE PROPERTY OF NXSTAGE MEDICAL, INC. AND MAY           FORM227
NOT BE REPRODUCED WITHOUT THE WRITTEN PERMISSION OF THE           Draft 1, Rev 1
MANAGEMENT OF NXSTAGE MEDICAL, INC.                                  Page 4 of 4
<PAGE>

EXHIBIT I - DEFINITION OF CHANGE OF CONTROL

     "CHANGE OF CONTROL" of the Company means and includes, consistent with
Section 409A of the Code, each and all of the following occurrences:

     (i) The stockholders of the Company approve a merger or consolidation of
the Company with any other corporation, other than a merger or consolidation
which would result in the voting securities of the Company outstanding
immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity
or its parent company) more than fifty percent (50%) of the total voting power
represented by the voting securities of the Company or such surviving entity, or
its parent company, outstanding immediately after such merger or consolidation,
or the stockholders of the Company approve a plan of complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or
substantially all the Company's assets.

     (ii) The acquisition by any Person as Beneficial Owner, directly or
indirectly, of securities of the Company representing fifty percent (50%) or
more of the total voting power represented by the Company's then outstanding
voting securities.

     (iii) A change in the composition of the Board of Directors of the Company
as a result of which fewer than a majority of the directors are "Incumbent
Directors." "Incumbent Directors" shall mean directors who either (A) are
directors of the Company as of the date hereof or (B) are elected, or nominated
for election, to the Board of Directors with the affirmative votes (either by a
specific vote or by approval of the proxy statement of the Company in which such
person is named as a nominee for election as a director without objection to
such nomination) of at least three-quarters of the Incumbent Directors at the
time of such election or nomination (but shall not include an individual whose
election or nomination is in connection with an actual or threatened proxy
contest relating to the election of directors of the Company).

     Any other provision of this Section notwithstanding, the term Change in
Control shall not include either of the following events undertaken at the
election of the Company:

     (x) Any transaction, the sole purpose of which is to change the state of
the Company's incorporation;

     (y) A transaction, the result of which is to sell all or substantially all
of the assets of the Company to another corporation (the "surviving
corporation"); provided that the surviving corporation is owned directly or
indirectly by the stockholders of the Company immediately following such
transaction in substantially the same proportions as their ownership of the
Company's Common Stock immediately preceding such transaction; and provided,
further, that the surviving corporation expressly assumes this Agreement.

<PAGE>

                                    EXHIBIT J

MDS is willing to provide NxStage with MDS' Confidential Information, and
NxStage is willing to provide MDS with NxStage's Confidential Information,
subject to the following provisions.

1.   NxStage agrees that it will treat all of MDS' Confidential Information as
     confidential and the property of MDS. NxStage agrees that it will not
     divulge any of MDS' Confidential Information to any third party without
     MDS' prior written consent. NxStage agrees that it will not use any of MDS'
     Confidential Information for its own benefit, except for the purpose of
     this Agreement. Additionally, NxStage agrees that it will not analyze any
     samples included in MDS' Confidential Information to determine the
     composition thereof, and agrees to return undestroyed samples at the
     request of MDS.

     MDS agrees that it will treat all of NxStage's Confidential Information as
     confidential. MDS agrees that it will not divulge any of NxStage's
     Confidential Information to any third party without NxStage's prior written
     consent. MDS agrees that it will not use any of NxStage's Confidential
     Information for its own benefit, except for the purpose of this Agreement.
     Additionally, MDS agrees that it will not analyze any samples included in
     NxStage's Confidential Information to determine the composition thereof,
     and agrees to return undestroyed samples at the request of NxStage.

     As used in this Agreement, the term "Confidential Information" means any
     technical or business information furnished by one party to the other party
     regardless of whether such information is specifically designated initially
     as confidential and regardless of whether such information is in written,
     oral, electronic, or other form. Such Confidential Information may include,
     without limitation, trade secrets, know-how, inventions, technical data,
     specifications, computer files, documentation control systems and contents,
     MRP systems and contents, computer programs, testing methods, business
     models, financial information, research and development activities, product
     designs, marketing plans, factory layouts, equipment, processes, customer
     lists, customer assessments, vendor lists and vendor assessments.

     MDS agrees that all of MDS' Confidential Information that is disclosed to
     NxStage by MDS and NxStage agrees that all of NxStage's Confidential
     Information that is disclosed to MDS by NxStage will be either:

     (a) in tangible form, where such tangible form is marked to indicate that
     it is confidential within one month of disclosure; or

     (b) in intangible form, where the substance of such intangible form of
     Confidential Information is documented in tangible form within one (1)
     month of such disclosure, and where such tangible form is marked to
     indicate that it is confidential. Notwithstanding the above but subject to
     Section 3 herein, the entire contents of and

<PAGE>

     processes conducted within each party's facilities are presumed to be the
     Confidential Information of such party and require no specific
     documentation by such party of each and every item of Confidential
     Information laid open to view by the other party. Facilities comprise the
     offices, factories, research and development facilities, etc. of the owning
     party as well as its vendors, to the degree such vendors are covered by
     appropriate confidentiality agreements of the relevant party.

2.   NxStage agrees that each of its officers, employees, consultants, vendors,
     etc. (hereafter "NxStage Personnel") that receives any of MDS' Confidential
     Information will be informed of and bound by the terms of this Agreement.
     Such NxStage Personnel will not be given access to any MDS Confidential
     Information until and unless they have entered into a separate written
     agreement with NxStage safeguarding NxStage's Confidential Information,
     where such separate agreement is applicable to MDS' Confidential
     Information, and binds such NxStage Personnel to the provisions of this
     Agreement in the same manner as NxStage is bound herein.

     MDS agrees that each of its officers, employees, consultants, vendors, etc.
     (hereafter "MDS Personnel") that receives any of NxStage's Confidential
     Information will be informed of and bound by the terms of this Agreement.
     Such MDS Personnel will not be given access to any NxStage Confidential
     Information until and unless they have entered into a separate written
     agreement with MDS safeguarding MDS' Confidential Information, where such
     separate agreement is applicable to NxStage's Confidential Information, and
     binds such MDS Personnel to the provisions of this Agreement in the same
     manner as MDS is bound herein.

3.   MDS agrees that any of MDS' Confidential Information that NxStage can show,
     by tangible evidence was in NxStage's possession prior to its disclosure
     will be released from the provisions of this Agreement. MDS agrees that any
     of MDS' Confidential Information that is, or which becomes, available to
     the public from a source other than from NxStage or NxStage Personnel,
     either directly or indirectly, will be released from the provisions of this
     Agreement. MDS agrees that any of MDS' Confidential Information that
     becomes available to NxStage legitimately and lawfully from a third party
     will be released from the provisions of this Agreement to the extent
     necessary to permit such use and disclosure as are permitted by such third
     party. MDS agrees that any of MDS' Confidential Information that is
     independently developed by NxStage Personnel that have no access to any
     relevant MDS Confidential Information, will be released from the provisions
     of this Agreement. NxStage agrees that MDS' Confidential Information shall
     not be deemed to be within one of the above exceptions merely because it is
     encompassed by a more general disclosure included within, or can be
     assembled by a selection of disclosures from, information within one of the
     above exceptions.

     NxStage agrees that any of NxStage's Confidential Information that MDS can
     show, by tangible evidence, was in MDS' possession prior to its disclosure
     will be released from the provisions of this Agreement. NxStage agrees that
     any of NxStage's Confidential Information that is, or which becomes,
     available to the public from a

<PAGE>

     source other than MDS or MDS Personnel, either directly or indirectly, will
     be released from the provisions of this Agreement. NxStage agrees that any
     of NxStage's Confidential Information that becomes available to MDS
     legitimately and lawfully from a third party will be released from the
     provisions of this Agreement to the extent necessary to permit such use and
     disclosure as are permitted by such third party. NxStage agrees that any of
     NxStage's Confidential Information that is independently developed by MDS'
     Personnel that have had no access to any relevant NxStage Confidential
     Information, will be released from the provision of this Agreement. MDS
     agrees that NxStage's Confidential Information shall not be deemed to be
     within one of the above exceptions merely because it is encompassed by a
     more general disclosure included within, or can be assembled by a selection
     of disclosures from, information within one of the above exceptions.

4.   NxStage agrees that nothing contained herein shall be construed as granting
     a right under any of MDS' intellectual property rights, except to the
     extent necessary for NxStage to accomplish the purpose of this Agreement.

     MDS agrees that nothing contained herein shall be construed as granting a
     right under any of NxStage's intellectual property rights, except to the
     extent necessary for MDS to accomplish the purpose of this Agreement.

5.   NXSTAGE AND MDS AGREE THAT THIS AGREEMENT SHALL BE GOVERNED BY, AND
     CONSTRUED ACCORDING TO, THE LAWS OF THE STATE OF WASHINGTON, UNITED STATES
     OF AMERICA

6.   NxStage and MDS agree that NxStage's obligation to protect MDS'
     Confidential Information shall terminate [**] years after disclosure of the
     Confidential Information in question, except in the instance of MDS trade
     secrets, which shall be defined to mean patentable inventions or processes,
     which shall remain confidential information hereunder in perpetuity until
     such trade secrets cease to be confidential information of MDS.

     MDS and NxStage agree that MDS' obligation to protect NxStage Confidential
     Information shall terminate [**] years after disclosure of the Confidential
     Information in question, except in the instance of NxStage trade secrets,
     which shall be defined to mean patentable inventions or processes, which
     shall remain confidential information hereunder in perpetuity until such
     trade secrets cease to be confidential information of NxStage.

7.   In the event that any party to whom Confidential Information is furnished
     becomes legally compelled to disclose such Confidential Information, such
     compelled party shall provide prompt notice thereof to the other party and
     the parties shall cooperate so that a protective order or other appropriate
     remedy may be sought and/or the other party may waive compliance with the
     provisions of this Agreement. In the event such protective order or other
     appropriate remedy is not obtained or that a waiver of the provisions
     hereof is not obtained, the party compelled to disclose shall

<PAGE>

     furnish only that portion of the Confidential Information that such
     compelled party is required to disclose, based on written opinion of
     counsel, and will exercise such party's best efforts to obtain reasonable
     assurance that confidential treatment will be accorded to such Confidential
     Information.

ACCEPTED AND AGREED TO THIS 4th DAY OF January, 2007

NXSTAGE MEDICAL, INC.                   MEDISYSTEMS CORPORATION

By: /s/ Jeffrey H. Burbank              By: /s/ David S. Utterberg
    ---------------------------------       ------------------------------------
    Jeffrey H. Burbank                      David S. Utterberg
    President & CEO                         President
<PAGE>

                                   Exhibit L
Nov. 14, 2006                 Open Book Accounting

<TABLE>
<CAPTION>
[**]   Q-3  Q-3 ADJUSTED  Q-1 T1  Q-2 T1-2  Q-3 T2  Q-4 T2  Q-1 T3  Q-2 T3  Q-3 T3  Q-4 T4  Q-1 T4  Q-2 T4  Q-3 T5  Q-4 T5
----  ----  ------------  ------  --------  ------  ------  ------  ------  ------  ------  ------  ------  ------  ------
<S>   <C>   <C>           <C>     <C>       <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[**]
[**]            [**]                         [**]                    [**]                    [**]            [**]
[**]  [**]      [**]
[**]  [**]      [**]       [**]     [**]     [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]
[**]  [**]      [**]       [**]     [**]     [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]
[**]  [**]      [**]       [**]     [**]     [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]    [**]
</TABLE>

<PAGE>

                                    Exhibit L
                              Open Book Accounting

<TABLE>
<CAPTION>
Q-1 T6  Q-2 T6  Q-3 T6-7  Q-4 T7  Q-1 T7  Q-2 T7-8  Q-3T8  Q-1 T9  Q-1 T9  Q-2 T9  Q-3 T10  Q-4 T10  Q-1 T10  Q-2 T10-11  Q-3 T11
------  ------  --------  ------  ------  --------  -----  ------  ------  ------  -------  -------  -------  ----------  -------
<S>     <C>     <C>       <C>     <C>     <C>       <C>    <C>     <C>     <C>     <C>      <C>      <C>      <C>         <C>
[**]                       [**]                      [**]           [**]                      [**]                          [**]
[**]     [**]     [**]     [**]    [**]     [**]     [**]   [**]    [**]    [**]     [**]     [**]     [**]      [**]       [**]
[**]     [**]     [**]     [**]    [**]     [**]     [**]   [**]    [**]    [**]     [**]     [**]     [**]      [**]       [**]
[**]     [**]     [**]     [**]    [**]     [**]     [**]   [**]    [**]    [**]     [**]     [**]     [**]      [**]       [**]
</TABLE>
<PAGE>

EXHIBIT M - RESERVED COST DOWNS

[**]

[**]

<TABLE>
<CAPTION>

                 TIER 1    TIER 2    TIER 3    TIER 4    TIER 5    TIER 6    TIER 7    TIER 8    TIER 9   TIER 10   TIER 11
               COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN
                [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO
               --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
<S>            <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>
SUBASSEMBLIES:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

MATERIAL :
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

EXTRUSION :
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

DIRECT LABOR:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

STERILIZATION:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

               --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
   TOTAL
               ========= ========= ========= ========= ========= ========= ========= ========= ========= ========= =========
</TABLE>

<PAGE>

EXHIBIT M - RESERVED COST DOWNS - PAGE 2

[**]

[**]

<TABLE>
<CAPTION>

                 TIER 1    TIER 2    TIER 3    TIER 4    TIER 5    TIER 6    TIER 7    TIER 8    TIER 9   TIER 10   TIER 11
               COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN COST DOWN
                [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO   [**]/MO
               --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
<S>            <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>       <C>
SUBASSEMBLIES:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

MATERIAL :
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

EXTRUSION :
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

DIRECT LABOR:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

STERILIZATION:
[**]           _________ _________ _________ _________ _________ _________ _________ _________ _________ _________ _________

               --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
   TOTAL
               ========= ========= ========= ========= ========= ========= ========= ========= ========= ========= =========
</TABLE>

<PAGE>

                                   EXHIBIT N

                        Complete costed Bill of Materials

Confidential materials omitted and filed separately with the Securities and
Exchange Commission.

[**]

<PAGE>

                                    EXHIBIT O

                    Examples of Revised Baseline Prices, etc.

Confidential materials omitted and filed separately with the Securities and
Exchange Commission.

[**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]